<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100555</article-id><article-id pub-id-type="doi">10.7554/eLife.100555</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100555.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Nonlinear transcriptional responses to gradual modulation of transcription factor dosage</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Domingo</surname><given-names>Júlia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6359-2785</contrib-id><email>julia.domingo.espinos@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Minaeva</surname><given-names>Mariia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7028-1264</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>John A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2769-8202</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Ghatan</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Ziosi</surname><given-names>Marcello</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Sanjana</surname><given-names>Neville E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1504-0027</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7746-8109</contrib-id><email>tlappalainen@nygenome.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wf2ga96</institution-id><institution>New York Genome Center</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/026vcq606</institution-id><institution>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>Department of Biology, New York University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Allostery Exploration Technologies, Barcelona, Spain</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Institute of Computational Biology, Helmholtz Center, Munich, Germany</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>01</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP100555</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-04"><day>04</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.01.582837"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-17"><day>17</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100555.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-11-25"><day>25</day><month>11</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100555.2"/></event></pub-history><permissions><copyright-statement>© 2024, Domingo et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Domingo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100555-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100555-figures-v1.pdf"/><abstract><p>Genomic loci associated with common traits and diseases are typically non-coding and likely impact gene expression, sometimes coinciding with rare loss-of-function variants in the target gene. However, our understanding of how gradual changes in gene dosage affect molecular, cellular, and organismal traits is currently limited. To address this gap, we induced gradual changes in gene expression of four genes using CRISPR activation and inactivation in human-derived K562 cells. Downstream transcriptional consequences of dosage modulation of three master trans-regulators associated with blood cell traits (<italic>GFI1B</italic>, <italic>NFE2</italic>, and <italic>MYB</italic>) were examined using targeted single-cell multimodal sequencing. We showed that guide tiling around the TSS is the most effective way to modulate <italic>cis</italic> gene expression across a wide range of fold changes, with further effects from chromatin accessibility and histone marks that differ between the inhibition and activation systems. Our single-cell data allowed us to precisely detect subtle to large gene expression changes in dozens of <italic>trans</italic> genes, revealing that many responses to dosage changes of these three TFs are nonlinear, including non-monotonic behaviours, even when constraining the fold changes of the master regulators to a copy number gain or loss. We found that the dosage properties are linked to gene constraint and that some of these nonlinear responses are enriched for disease and GWAS genes. Overall, our study provides a straightforward and scalable method to precisely modulate gene expression and gain insights into its downstream consequences at high resolution.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>gene expression</kwd><kwd>gene regulation</kwd><kwd>transcription factors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0s7x83</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>R01MH106842</award-id><principal-award-recipient><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049v75w11</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01AG057422</award-id><principal-award-recipient><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00baak391</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>DP2HG010099</award-id><principal-award-recipient><name><surname>Sanjana</surname><given-names>Neville E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00baak391</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>R01HG012790</award-id><principal-award-recipient><name><surname>Sanjana</surname><given-names>Neville E</given-names></name><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q48ey07</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM122924</award-id><principal-award-recipient><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/004hzzk67</institution-id><institution>Knut and Alice Wallenberg Foundation</institution></institution-wrap></funding-source><award-id>KAW 2020.0239</award-id><principal-award-recipient><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0472cxd90</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.3030/101043238</award-id><principal-award-recipient><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wfr2810</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>ALTF 345-2021</award-id><principal-award-recipient><name><surname>Domingo</surname><given-names>Júlia</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01gavpb45</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Morris</surname><given-names>John A</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00baak391</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>K99HG012792</award-id><principal-award-recipient><name><surname>Morris</surname><given-names>John A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A new CRISPR-based approach for tuning gene expression up and down allowed identification of how other genes' expression responds to changes of transcription factors.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Precision control of gene expression levels plays a pivotal role in defining cell type specificity and coordinating responses to external stimuli. Imbalances in this intricate regulation can underlie the genetic basis of both common and rare human diseases. The vast majority of genetic variants associated with complex disease, as revealed by genome-wide association studies (GWAS), are located in noncoding regions, with likely gene regulatory effects (<xref ref-type="bibr" rid="bib38">Maurano et al., 2012</xref>). Previous studies have attempted to elucidate these effects by mapping genetic associations to gene expression (<xref ref-type="bibr" rid="bib1">Aguet et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Claussnitzer et al., 2020</xref>), and more recently, CRISPR-based perturbations of GWAS loci have provided insights into their functional consequences (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). A major driver of rare genetic diseases is loss-of-function variants affecting one or both copies of the gene, leading to disease via dramatic reduction of functional gene dosage (<xref ref-type="bibr" rid="bib65">Zschocke et al., 2023</xref>). The substantial overlap (<xref ref-type="bibr" rid="bib3">Backman et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Freund et al., 2018</xref>) and potential joint effects (<xref ref-type="bibr" rid="bib7">Castel et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Fahed et al., 2020</xref>) of rare and common variants indicate a general link between different degrees of perturbation of gene dosage and disease phenotypes.</p><p>However, our understanding of the quantitative relationship between gradual changes in gene dosage and downstream phenotypes remains elusive for most human genes. Practical applications of the compelling allelic series concept to identify genes where increasingly deleterious mutations have increasing phenotypic effects have been limited by the sparsity of segregating variants with an impact on a given gene in the human population (<xref ref-type="bibr" rid="bib39">McCaw et al., 2023</xref>). Experimental characterization of gene function in model systems has predominantly relied on gene knock-out or knock-down approaches (<xref ref-type="bibr" rid="bib55">Sanjana, 2017</xref>). While these studies have proven useful to identify dosage-sensitive genes involved in cellular functions and disease (<xref ref-type="bibr" rid="bib11">Collins et al., 2022</xref>; <xref ref-type="bibr" rid="bib18">Fehrmann et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Hart et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Cowley et al., 2014</xref>), these approaches only provide a limited discrete relationship between the number of functional gene copies and a certain phenotype (e.g. loss-of-function consequence vs. wild-type). However, such relationships are in fact determined by continuous dosage-to-phenotypes functions that, as suggested by a small number of previous experimental studies (<xref ref-type="bibr" rid="bib29">Keren et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Hawkins et al., 2020</xref>), can be complex and thus are challenging to infer from loss-/gain-of-function data.</p><p>Recently, new methods have enabled the gradual modulation of gene dosage in model systems (<xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Noviello et al., 2023</xref>; <xref ref-type="bibr" rid="bib8">Chiarella et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Liu et al., 2024</xref>), while large-scale insights into the downstream effects of dosage modulation have largely come from yeast (<xref ref-type="bibr" rid="bib29">Keren et al., 2016</xref>) and bacteria (<xref ref-type="bibr" rid="bib24">Hawkins et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Lalanne et al., 2021</xref>), demonstrating that nonlinear relationships between gene dosage and phenotype are common. In humans, the relationship between dosage and downstream phenotypes is largely unexplored. Only a few limited studies (<xref ref-type="bibr" rid="bib29">Keren et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Hawkins et al., 2020</xref>) have dissected these consequences. For instance, the disease-associated transcription factor <italic>SOX9</italic> (<xref ref-type="bibr" rid="bib48">Naqvi et al., 2023</xref>) showed a nonlinear relationship between dosage and multiple tiers of phenotypes, including DNA accessibility, RNA expression of downstream targets, raising the question of whether this phenomenon occurs with other transcription factors. More recently, similar evidence has been shown in the case of the <italic>NKX2-1</italic> lineage factor with an oncogenic role in lung adenocarcinoma (<xref ref-type="bibr" rid="bib51">Pulice and Meyerson, 2023</xref>). Generally, transcription factors represent a particularly compelling target for the characterization of gene dosage effects. They are key regulators of cellular functions, enriched for disease associations (<xref ref-type="bibr" rid="bib47">Mostafavi et al., 2023</xref>) and often classified as haploinsufficient (<xref ref-type="bibr" rid="bib61">van der Lee et al., 2020</xref>). Additionally, their effects can be measured by transcriptome analysis. However, our knowledge of their dosage-dependent effects on regulatory networks still remains limited, particularly regarding subtle dosage variation within their natural range (<xref ref-type="bibr" rid="bib34">Liu et al., 2024</xref>).</p><p>In this study, we developed and characterized a scalable novel sgRNA design approach for gradually decreasing and increasing gene dosage with the CRISPR interference (CRISPRi) and activation (CRISPRa) systems. We applied this to four genes, with single-cell RNA sequencing (scRNA-seq) as a cellular readout of downstream effects. While classic Perturb-Seq analyses have focused on gene knockdown effects, we assess the effects of gradual up- and down-regulation of target genes. We uncovered quantitative patterns of how gradual changes in transcription dosage lead to linear and nonlinear responses in downstream genes. Many downstream genes are associated with rare and complex diseases, with potential effects on cellular phenotypes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Precise modulation and quantification of gene dosage using CRISPR and targeted multimodal single-cell sequencing</title><p>We selected four genes for gradual modulation of their dosage in the human erythroid progenitor cell line K562 (<xref ref-type="bibr" rid="bib60">Ulirsch et al., 2016</xref>): <italic>GFI1B</italic>, <italic>NFE2</italic>, <italic>MYB,</italic> and <italic>TET2</italic>. Two of the genes, <italic>GFI1B</italic> and <italic>NFE2</italic>, have been implicated in blood diseases and traits (<xref ref-type="bibr" rid="bib45">Möröy et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Polfus et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Jutzi et al., 2019</xref>), and in our earlier work, we identified a broad transcriptional response to inhibition of GWAS-overlapping enhancers to these genes (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). <italic>MYB</italic> is a key transcription factor (<xref ref-type="bibr" rid="bib4">Baker et al., 2014</xref>) and a downstream target of <italic>GFI1B</italic> (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). <italic>TET2</italic> has a role in DNA demethylation and is unrelated to these transcriptional networks and is included in this study as a control with minimal expected <italic>trans</italic> effects. We refer to these four genes, targeted in cis for modulation of their regulation, as <italic>cis</italic> genes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Modulation and quantification of gene dosage using CRISPR and targeted multimodal single-cell sequencing.</title><p>(<bold>A</bold>) Co-expression network representation of the 92 selected genes under study. Genes (nodes) are connected by edges when their co-expression across single cells was above 0.5 (data used from <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). Highlighted in colour are the two control highly (GAPDH) and lowly (LHX3) constantly expressed genes, as well as cis genes for which dosage was modulated with CRISPRi/a. (<bold>B</bold>) Design of the multimodal single-cell experiment (HTO = hash tag oligos). (<bold>C</bold>) Distribution of the GFI1B (left) or NFE2 (right) normalized expression across single cells for different classes of sgRNAs (NTC = Non-targeting controls, TSS = transcription start site). (<bold>D</bold>) Resulting relative expression change (log2 fold change) of the 4 cis genes upon each unique CRISPR perturbation when grouped across different classes of sgRNAs. (<bold>E</bold>) Distribution of cis gene log2FC across all sgRNA perturbations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Experimental design and data processing from UMIs to expression fold change, related to <xref ref-type="fig" rid="fig1">Figure 1</xref> and STAR methods.</title><p>(<bold>A</bold>) Co-expression matrix of the 76 selected GFI1B trans genes based on K562 data from <xref ref-type="bibr" rid="bib38">Maurano et al., 2012</xref>. Three clusters from the selected targeted panel show similar co-expression architecture than the original clusters identified using the entire GFI1B trans-network (original clusters A in blue, B in green and C in red). (<bold>B</bold>) Same as A for the 39 NFE2 trans genes (original clusters A in green, B in orange, C in blue, and D in red). (<bold>C</bold>) Correlation between total UMI counts per gene between 10 X chip lanes. Targeted panel genes are shown in orange and highlighted names correspond to dosage genes (NFE2, MYB, GFI1B, and TET2) and low/high expression controls (LHX3 and GAPDH). (<bold>D</bold>) The number of singlet cells carrying each sgRNA in the two different CRISPR cell lines. NTC = non-targeting controls. (<bold>E</bold>) Q-Q plots from Sceptre calibration test. (<bold>F</bold>) Distribution of normalized UMI expression of the cis gene labelled on top for cells with single guide RNAs (sgRNAs) targeting their transcription start site (TSS) or harbouring non-targeting control (NTC) sgRNAs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Biochemical and activity properties of different types of single guide RNAs (sgRNAs).</title><p>(<bold>A</bold>) Relationship between off-target and on-target activity of sgRNAs and the change in expression of their target cis gene. (<bold>B</bold>) The relationship between the number of cells that covered each sgRNA perturbation with the absolute fold change of the cis gene (top) or the number of differentially expressed trans genes due to the cis gene perturbation (bottom). (<bold>C</bold>) The relationship between the location of the mismatch mutation of attenuated sgRNAs (position 1 being farthest away from protospacer adjacent motif (PAM) motif location) and their effect on the cis gene expression.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Gradual effects of the single guide RNAs (sgRNAs).</title><p>(<bold>A</bold>) Distribution of the normalized cis gene UMIs in single cells, grouped by their unique sgRNAs, ranked top to bottom by mean normalized expression. Transparent distributions correspond to non-targeting controls. (<bold>B</bold>) Distribution of the correlation in trans gene expression fold changes when splitting the same sgRNA cells into 0 UMI or &gt;0 UMI for the cis gene (top panel). Comparison of the strength of these correlations with the effect of that sgRNA on the cis gene (bottom panel). The size of dots indicates the difference in the size of the 0 UMI or &gt;0 UMI cell groups. (<bold>C</bold>) UMAPs of the cells with GFI1B, MYB, and NFE2 guides together with non-targeting guides. The left and right clusters in each figure represent CRISPRa and CRISPRi cells, respectively. The cells are coloured by the median fold change associated with their sgRNA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig1-figsupp3-v1.tif"/></fig></fig-group><p>To modulate the gene expression of the <italic>cis</italic> genes, we use K562 cells expressing CRISPRi (KRAB-dCas9-MECP2) and CRISPRa (dCas9-VPR) systems (see Methods). Both cell lines were hashed with DNA-conjugated antibodies against different surface proteins that allow pooled experiments. To obtain a wide range of dosage effects, we used four different single guide RNA (sgRNA) design strategies (<xref ref-type="fig" rid="fig1">Figure 1B</xref>): (1) targeting the transcription start site (TSS) as in the standard CRISPRi/CRISPRa approach, (2) tiling sgRNAs +/-1000 bp from the TSS in approximately 100 bp intervals, (3) targeting known <italic>cis</italic>-regulatory elements (CREs), and (4) using attenuated guides that target the TSS but contain mismatches to modulate their activity (<xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>). We further included five non-targeting control (NTC) sgRNAs as negative controls.</p><p>The library of altogether 96 guides was transduced to a pool of K562-CRISPRi and K562-CRISPRa cells at low multiplicity of infection (MOI). After eight days, we performed ECCITE-seq (see Methods) to capture three modalities: cDNA, sgRNAs, and surface protein hashes (oligo-tagged antibodies with unique barcodes against ubiquitously expressed surface proteins). Instead of sequencing the full transcriptome, we used target hybridization to capture a smaller fraction of the cDNA and obtain more accurate expression readouts at a feasible cost. The subset of selected transcripts were picked from the transcriptional downstream regulatory networks of <italic>GFI1B</italic> and <italic>NFE2</italic> identified previously (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>), maintaining similar patterns of co-expression correlation across co-expression clusters (see Methods, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We targeted a total of 94 transcripts (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), including the four <italic>cis</italic> genes, 86 genes that represent trans targets of <italic>GFI1B</italic> and/or <italic>NFE2</italic> (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), <italic>LXH3</italic> that is not expressed in blood progenitors, <italic>GAPDH</italic> that is highly expressed and often considered an invariable housekeeping gene and the dCas9-VPR or KRAB-dCas9-MeCP2 transcripts.</p><p>We used the protein hashes and the dCas9 cDNA (indicating the presence or absence of the KRAB domain) to demultiplex and determine the cell line—CRISPRi or CRISPRa. Cells containing a single sgRNA were identified using a Gaussian mixture model (see Methods). Standard quality control procedures were applied to the scRNA-seq data (see Methods). To confirm that the targeted transcript capture approach worked as intended, we assessed concordance across capture lanes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). The final data set had 20,001 cells (10,647 CRISPRi and 9354 CRISPRa), with an average of 81 and 86 cells with a unique sgRNA for the CRISPRa and CRISPRi, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p></sec><sec id="s2-2"><title>Gradual modulation of gene expression across a broad range with CRISPRi/a</title><p>Next, we calculated the expression fold change for each of the four <italic>cis</italic> genes targeted by each sgRNA in the two cell lines (CRISPRi/a), comparing each group of cells with its respective NTC sgRNA group (see Methods). We first confirmed that the sgRNAs targeting the transcription start site (TSS) up- and down-regulated their targets (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). When looking at all sgRNAs at once, across the four genes, we observed a 2.3-fold range (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), with a minimum 72% reduction and maximum 174% increased expression (log2(FC) values from –1.83–0.80). However, the range varied between the genes, with <italic>GFI1B</italic> covering the widest range of gene expression changes (gene expression ranging between 0.28–1.42 fold), while <italic>MYB</italic> expression could not be pushed higher than 1.13 fold (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The direction of the effects were consistent with the cell lines of origin, where 98.88% of the significant perturbations (Wilcoxon rank test at 10% FDR, n=89) were correctly predicted based on the direction of the target gene fold change. The predicted on- and off-target properties of the guides (<xref ref-type="bibr" rid="bib13">Doench et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Doench et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">McKenna and Shendure, 2018</xref>) did not correlate with the fold changes in the <italic>cis</italic> genes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>), suggesting that the observed effects represent true <italic>cis</italic>-regulatory changes. The fold changes were also robust to the number of cells containing a particular sgRNA (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>, top).</p><p>We verified that the fold change estimation was not biased depending on the expression level of the target gene at the single-cell level, which can vary due to drop-out effects or binary on/off effects of the KRAB-based CRISPRi system (<xref ref-type="bibr" rid="bib49">Noviello et al., 2023</xref>). By splitting cells with the same sgRNA based on the normalized expression of the <italic>cis</italic> gene (0 vs. &gt;0 normalized UMIs, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>), we observed highly concordant transcriptome gene expression effects between the two groups (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). This indicates that the dosage changes per guide were not primarily driven by the changing frequency of binary on/off effects, and the use of pseudo-bulk fold changes provides a robust estimation of <italic>cis</italic> gene fold changes. These patterns are further supported by the cells forming a gradient rather than distinct clusters on a UMAP (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>).</p><p>The fold change patterns differed between sgRNA designs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, left). As expected, sgRNAs targeting the TSS showed strong perturbations in gene expression. However, sgRNAs tiled +/-1 kb from the TSS provided a broader and more gradual range of up- and downregulation across the target genes, sometimes surpassing the effects of TSS-targeting sgRNAs. Attenuated sgRNAs with mismatch mutations resulted in a range of gene silencing effects in the CRISPRi line, as expected based on their original design (<xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>). However, these attenuated sgRNAs did not exhibit such a dynamic range in the CRISPRa modality, although a significant correlation existed between the silencing or activating effect size and the distance of the mismatch from the protospacer adjacent motif (PAM) when considering all data points together (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). The sgRNAs targeting distal <italic>cis</italic>-regulatory elements (CREs) showed both inhibiting and activating effects, even though both the CRISPRi and CRISPRa constructs were initially designed to inhibit or activate transcription from the promoter and initial gene body region. Nonetheless, the number of known CREs per gene is typically limited. Given its simplicity and the ability to achieve both up- and downregulation of the target gene, we consider the tiling sgRNA approach, with a simple design that only requires annotation of the TSS, as a useful method for gradually modulating gene dosage with CRISPRi/a systems.</p></sec><sec id="s2-3"><title><italic>Cis</italic> determinants of dosage</title><p>Having designed guides targeting both distal and local neighbouring regulatory regions of the four transcription factors (TFs) and ensuring minimal bias in fold changes due to sgRNA’s biochemical properties, we investigated the <italic>cis</italic> features that determine the strength of dosage perturbation. We observed substantial differences in the effects of the same guide on the CRISPRi and CRISPRa backgrounds, with no significant correlation between <italic>cis</italic> gene fold changes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, in both modalities, the strongest effects on gene expression were observed when the guides were close to the transcription start site (TSS) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, excluding NTC and attenuated sgRNAs), although the peaks of strongest activation or repression differed between the modalities. In the CRISPRi modality, the maximum effect was located within the gene body at +238 bp from the TSS (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, bottom), consistent with previous studies that used essentiality as a proxy for expression (<xref ref-type="bibr" rid="bib56">Sanson et al., 2018</xref>). However, in the CRISPRa modality, the maximum average fold changes occurred closer to the TSS at around –99 bp (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, bottom), as also shown for CD45 (<xref ref-type="bibr" rid="bib31">Legut et al., 2020</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cis determinants of dosage.</title><p>(<bold>A</bold>) Comparison of the relative expression change (log2FC) from the same single guide RNA (sgRNA) between the two different CRISPR modalities. Vertical and horizontal bars represent CRISPRa and CRISPRi standard errors, respectively. (<bold>B</bold>) Relative expression change of the targeted cis gene based on distance from transcription start site (TSS). Top plot excluded attenuated and non-targeting control (NTC) sgRNAs, while bottom plot also excludes enhancer sgRNAs. (<bold>C</bold>) Number of sgRNAs that overlap with the different epigenetic or open chromatin peaks. (<bold>D</bold>) Relative expression change to NTC sgRNAs (log2(FC)) of all cis genes when their sgRNAs fall or not in the different epigenetic or open chromatin peaks. P-value results from Wilcoxon rank-sum tests, with nominally significant p-values shown in black.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig2-v1.tif"/></fig><p>Enhancer, tiling, and TSS sgRNAs targeted regions of the genome with different compositions of histone marks, annotated by ENCODE, in K562 cells (<xref ref-type="bibr" rid="bib35">Luo et al., 2020</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref>), which allowed us to investigate the impact of chromatin state on the strength of <italic>cis</italic> gene dosage modulation. The magnitude of <italic>cis</italic> gene fold changes varied significantly depending on the presence of specific marks or peaks, which again differed between the two modalities (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). In the CRISPRa cell line, the strongest effects were observed when guides were located in regions with open chromatin marks, such as DNase or ATAC peaks. In contrast, the strongest repression by CRISPRi occurred in genomic regions with the presence of H3K27ac, H3K4me3, and H3K9ac marks. These differences may be explained by the distinct mechanisms of action of the activator and repressor domains. MeCP2 and KRAB repressor domains recruit additional repressors that silence gene expression through chromatin remodelling activities, such as histone deacetylation (<xref ref-type="bibr" rid="bib36">Lupo et al., 2013</xref>). On the other hand, the VPR activation fusion domain may only require Cas9 to scan the open chromatin and recruit RNA polymerase and additional transcription factors to activate transcription. Overall, while a few sgRNAs have a strong effect in both CRISPRi and CRISPRa cell lines, a single guide library containing guides optimized for both modalities enables a range of gradual dosage regulation. However, larger data sets are needed for more careful modelling of the ideal dosage modulation designs and to understand how both <italic>cis</italic>-regulatory features, feedback loops, and other mechanisms contribute to the outcomes.</p></sec><sec id="s2-4"><title><italic>Trans</italic> responses of transcription factor dosage modulation</title><p>We then turned our attention to the remaining 91 genes captured by our custom panel and determined the relative expression fold change of each <italic>trans</italic> gene, compared to NTC in each unique guide perturbation (see Methods). Principal component analysis (PCA) performed on all pseudo-bulk fold changes demonstrated the removal of batch effects from the cell lines and revealed a clear direction of the <italic>cis</italic> gene dosage effect in the first three principal components (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). This finding suggests that dosage modulation is the primary determinant of <italic>trans</italic> effects. The PCA indicated that the dosage modulation of <italic>GFI1B</italic> and <italic>MYB</italic> is reflected in opposite directions in PC1 and PC2, while the <italic>trans</italic> responses of <italic>NFE2</italic> are captured by PC3.</p><p>Using a false discovery rate (FDR) cutoff of 0.05, all 91 <italic>trans</italic> genes except for the neural-specific TF <italic>LHX3</italic> (negative control) exhibited a significant change in expression upon perturbation of any of the TFs. The observed trans-effects were well correlated with perturbations of these genes in other data sets (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>). Among all measured fold changes, the most extreme negative effect sizes were observed in cis genes, with the top 10 being predominantly reductions in <italic>GFI1B</italic> expression. This indicates that <italic>cis</italic> downregulation tended to surpass the endogenous expression limits. In contrast, the largest increases in gene expression were observed through <italic>trans</italic> mechanisms, where <italic>KLK1</italic> and <italic>TUBB1</italic> reached the largest expression values when <italic>GFI1B</italic> was strongly upregulated, or <italic>SPI1</italic> and <italic>DAPK1</italic> when <italic>GFI1B</italic> was strongly downregulated. These findings suggest that the CRISPRa approach did not reach a biological ceiling of overexpression.</p><p>Inspecting <italic>trans</italic> responses as a function of <italic>cis</italic> gene modulation, we observed that the number of expressed genes and the mean absolute expression changes of <italic>trans</italic> genes exhibited gene-specific correlations with <italic>cis</italic>-gene dosage (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Perturbations in <italic>GFI1B</italic> led to the most pronounced <italic>trans</italic> responses, with positive dosage changes resulting in larger effect sizes compared to decreasing TF gene expression, where the effect plateaued. <italic>NFE2</italic> exhibited similar patterns but with a smaller magnitude. In the case of <italic>MYB</italic>, <italic>trans</italic> responses were observed when decreasing the expression of this TF, but the effects of upregulation are largely unknown as we were unable to increase <italic>MYB</italic> expression beyond 0.35. As expected, given the unrelatedness of <italic>TET2</italic> to the <italic>trans</italic> network, dosage modulation of this gene had minimal <italic>trans</italic> effects with the least pronounced trend when compared to <italic>TET2</italic> dosage, so we excluded it from subsequent analyses.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Trans responses of transcription factor dosage modulation.</title><p>(<bold>A</bold>) Average absolute expression change of all trans genes relative to the changes in expression of the cis genes. (<bold>B</bold>) Changes in relative expression of all trans genes (bottom heatmap) in response to GFI1B expression changes (top barplot) upon each distinct targeted single guide RNA (sgRNA) perturbation, in comparison to non-targeting control (NTC) cells. The rows of the heatmap (trans genes) are hierarchically clustered based on their expression fold change linked to alterations in GFI1B dosage. Highlighted rows are selected dosage response examples shown in C. (<bold>C</bold>) Dosage response curves of the highlighted trans gene in B as a function of changes in GFI1B expression. The orange line represents the sigmoid model fit, except for GATA2, which displays a non-monotonic response and are fitted with a loess curve. (<bold>D</bold>) Illustration of the linear and sigmoid models and equations used to fit the dosage response curves. (<bold>E</bold>) Distribution of the difference in Akaike Information Criterion (ΔAIC<sub>linear-sigmoid</sub>) after fitting the sigmoidal or linear model for each trans gene upon GFI1B dosage modulation (top panel), and the direct comparison of the Akaike Information Criterion (AIC) of each fit (bottom panel).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Global view of trans effects and their replication.</title><p>(<bold>A</bold>) Principal component analysis (PCA) of mean UMI normalized expression (not relative to each cell line of origin) for all genes across unique single guide RNA (sgRNA) perturbations. (<bold>B</bold>) Same as A but using relative expression fold-change when normalising by the CRISPR cell line of origin. (<bold>C</bold>) Replication of trans-effects of CRISPRi of CREs for GFI1B and NFE2, targeted both in this study (x-axis) and in <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref> (y-axis). GFI1B CRE 1 and NFE2 CRE 1 were targeted in Morris et al. data batches V1 and V2, and the effects are shown here for both separately. (<bold>D</bold>) Replication of trans-effects from transcription start site (TSS) silencing in this study and in <xref ref-type="bibr" rid="bib52">Replogle et al., 2022</xref>, analysing guides from this study that target transcription start sites, but the guides do not fully match the exact guides used in Replogle et al. The effect size in Replogle et al. is quantified using their metric of Wilcox mean difference. The dashed line represents a linear regression line between the x and y variables. (<bold>E</bold>) Number of differentially expressed trans genes relative to the cis gene dosage perturbation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Trans gene responses to GFI1B dosage modulation.</title><p>(<bold>A</bold>) Changes in relative expression of all trans genes (heatmap) in response to GFI1B expression (top barplot) upon each distinct targeted single guide RNA (sgRNA) perturbation. The rows of the heatmap (trans genes) are hierarchically clustered based on their expression fold change linked to alterations in GFI1B dosage. (<bold>B</bold>) Dosage response curves are plotted for each trans gene against changes in GFI1B expression. The orange line represents the sigmoid model fit, and the blue line represents a loess curve.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Trans gene responses to MYB dosage modulation.</title><p>(<bold>A</bold>) Changes in relative expression of all trans genes (bottom heatmap) in response to MYB expression (top barplot) upon each distinct targeted GFI1B single guide RNA (sgRNA) perturbation. The rows of the heatmap (trans genes) are hierarchically clustered based on their expression fold change linked to alterations in MYB dosage. (<bold>B</bold>) Dosage response curves are plotted for each trans gene against changes in MYB expression. The orange line represents the sigmoid model fit.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Trans gene responses to NFE2 dosage modulation.</title><p>(<bold>A</bold>) Changes in relative expression of all trans genes (bottom heatmap) in response to NFE2 expression (top barplot) upon each distinct targeted NFE2 sgRNA perturbation. The rows of the heatmap (trans genes) are hierarchically clustered based on their expression fold change linked to alterations in NFE2 dosage. (<bold>B</bold>) Dosage response curves are plotted for each trans gene against changes in NFE2 expression. The orange line represents the sigmoid model fit.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp4-v1.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>Trans gene responses to TET2 dosage modulation.</title><p>(<bold>A</bold>) Changes in relative expression of all trans genes (bottom heatmap) in response to TET2 expression (top barplot) upon each distinct targeted TET2 single guide RNA (sgRNA) perturbation. The rows of the heatmap (trans genes) are hierarchically clustered based on their expression fold change linked to alterations in TET2 dosage. (<bold>B</bold>) Dosage response curves are plotted for each trans gene against changes in TET2 expression. The orange line represents the sigmoid model fit.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp5-v1.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Dosage response linear and non-linear model fitting.</title><p>(<bold>A</bold>) Distribution of the difference in Akaike Information Criterion (ΔAIC<sub>linear-sigmoid</sub>) after fitting the sigmoidal or linear model for each trans gene based on the gradual expression perturbations of the four cis genes (top panel), and the direct comparison of the Akaike Information Criterion (AIC) of each fit (bottom panel). Red lines indicate median ∆AIC. (<bold>B</bold>) Same as A but only fitting the models on those single guide RNA (sgRNA) perturbations that lead to a cis gene dosage change bounded between log2(1/2) and log2(3/2). (<bold>C</bold>) Agreement between observed and predicted trans genes expression fold change upon cis gene dosage modulation across a 10-fold cross-validation scheme. (<bold>D</bold>) Comparison of the Root Mean Square Error (RMSE) of the sigmoid model on the different trans genes dosage responses to the RMSE of the equivalent loess fit (bottom panel). In blue are highlighted the non-monotonic responses that correspond to the top four ΔRMSE<sub>sigmoid-loess</sub> (RMSE<sub>sigmoid</sub> - RMSE<sub>loess</sub>) values (top panel).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp6-v1.tif"/></fig><fig id="fig3s7" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 7.</label><caption><title>Distribution of the fitted parameters of the sigmoidal model on dosage responses.</title><p>Cumulative distribution of the four fitted parameters (first four columns) of the sigmoid model across genes given the independent perturbation of the four transcription factors (TFs) (rows). slope_IF = slope of dosage response curve at the inflection point, min_asmp = minimum asymptote (minimum trans gene dosage level), max_asmp = maximum asymptote (maximum trans gene dosage level), x_IF = TF expression FC at the dosage response inflection point.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig3-figsupp7-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Widespread nonlinear dosage responses in <italic>trans</italic> regulatory networks</title><p>Upon clustering the changes in expression of <italic>trans</italic> genes based on the <italic>cis</italic> gene dosage change linked to each sgRNA, we identified distinct clusters exhibiting different dosage-response patterns (<xref ref-type="fig" rid="fig3">Figure 3B</xref> for <italic>GFI1B</italic>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref>–<xref ref-type="fig" rid="fig3s5">5A</xref> for all <italic>cis</italic> genes). Further examination of the gene expression fold changes for each individual trans gene in relation to the TF fold changes revealed a diverse range of response patterns (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref>–<xref ref-type="fig" rid="fig3s5">5B</xref> for all <italic>cis</italic> genes). These responses exhibited both linear and nonlinear forms, including some instances of non-monotonic gene expression responses for certain <italic>trans</italic> genes within the <italic>GFI1B</italic> trans network (e.g. <italic>GATA2</italic> in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6E</xref>).</p><p>To accurately characterise the dosage response, we employed both linear and nonlinear modelling approaches (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), which allowed us to quantitatively assess the extent of nonlinear responses by comparing the goodness of fit of these models using the Akaike Information Criterion (AIC). For the nonlinear model, we utilized a sigmoid function with four free parameters (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, right). These parameters represented the slope at the inflection point (<italic>b</italic>, indicating the rate of increase or decrease in expression), the minimum and maximum asymptotes (<italic>c</italic> and <italic>d</italic>, representing the lower and upper limits of fold change), and the value of <italic>cis</italic> gene expression at which the inflection point occurs (<italic>a</italic>). To prevent overfitting, we implemented a 10-fold cross-validation scheme, which yielded reliable predictions on the left-out data (Pearson <italic>r</italic>=0.71–0.88 for all <italic>trans</italic> genes in the <italic>GFI1B</italic>, <italic>MYB</italic>, and <italic>NFE2</italic> networks, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6C</xref>). Additionally, the predicted parameter <italic>a</italic> was centred around zero, as expected, since the input data represents relative fold changes (<xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7</xref>). Since a sigmoid function cannot capture non-monotonic responses, we employed a loess regression as an alternative approach for the few genes that exhibited non-monotonic responses (see Methods, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6D and E</xref>). For the vast majority of genes, the sigmoid (or loess) fit was remarkably good, partially due to the low level of noise in the targeted scRNA-seq data.</p><p>We compared the performance of the linear vs. nonlinear models with the ∆AIC (<inline-formula><alternatives><mml:math id="inf1"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft1">\begin{document}$AIC_{linear} -\, AIC_{r}$\end{document}</tex-math></alternatives></inline-formula>), where a positive ∆AIC means that the sigmoid model captures the variance better in the dosage response than in the linear model. This showed that most <italic>GFI1B</italic>-dependent dosage expression responses are better fit by the sigmoid model (median ∆AIC = 18.7, with 70.4% of all <italic>trans</italic> genes with a significant response having ∆AIC &gt;2, <xref ref-type="fig" rid="fig3">Figure 3E</xref>). The responses to dosage modulation of <italic>MYB</italic> and <italic>NFE2</italic> were also better captured by the nonlinearities, but to a lesser extent (0.14 and 3.4 median ∆AIC, with 20.8% and 40.7% of all <italic>trans</italic> genes dosage responses having ∆AIC &gt;2 for <italic>MYB</italic> and <italic>NFE2</italic>, respectively, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6A</xref>). The broader range of <italic>GFI1B</italic> expression modulation, providing more data to detect nonlinear trends, likely contributes to this difference. When ignoring those genes classified as unresponsive (genes that their expression did not change upon the TF modulator, see Methods), even more responses of the remaining <italic>trans</italic> genes were better explained by a sigmoidal model with 83.6%, 26.3%, and 63.2% of these having a ∆AIC &gt;2, for <italic>GFI1B</italic>, <italic>MYB,</italic> and <italic>NFE2</italic> respectively. A similar trend holds even when limiting the models to be fitted to those data points that correspond to a hypothetical one copy loss or gain of the <italic>cis</italic> gene (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6B</xref>), where the median ∆AIC of responsive genes are 7.05, 0.05, and 3.6 for <italic>GFI1B</italic>, <italic>MYB,</italic> and <italic>NFE2 trans</italic> responses. Overall, this shows that <italic>trans</italic> responses to TF dosage are dominated by nonlinear behaviours even when the TF dosage changes are not extreme but within biologically plausible ranges.</p></sec><sec id="s2-6"><title>Gene and transcriptional network properties of dosage response</title><p>Utilising a model that effectively captures the variance in our data provided the ability to predict unmeasured TF dosage points and facilitated a direct comparison of <italic>trans</italic> effects across different cis genes. Employing the sigmoid model (and loess for those with non-monotonic responses), we estimated the continuous expression of <italic>trans</italic> genes on a uniform fold-change scale across the spectrum of <italic>GFI1B</italic>, <italic>MYB</italic>, and <italic>NFE2</italic> expression changes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This estimation was carried out within the empirically observed range of all three <italic>cis</italic> genes, spanning from log2(FC) –1.83–0.51. Subsequent hierarchical clustering of <italic>trans</italic> gene responses revealed six major clusters of distinct response patterns. For the majority of <italic>trans</italic> genes, the response to <italic>GFI1B</italic> and <italic>MYB</italic> was opposite, with only two small clusters displaying exceptions. Notably, <italic>GFI1B</italic> generally induced the most substantial response, while <italic>NFE2</italic> triggered the smallest range of <italic>trans</italic> gene response.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Relationship between gene and dosage response properties.</title><p>(<bold>A</bold>) Predicted changes (using sigmoid or loess fits for monotonic and non-monotonic responses, respectively) in relative expression of all trans genes in response to changes of the GFI1B, MYB, and NFE2 expression. Trans genes (rows) were hierarchically clustered based on their expression fold change linked to alterations of all transcription factors (TFs) dosage. A dendrogram of the resulting clustering shown in the left. (<bold>B</bold>) Heatmap showing the qualitative properties of each trans gene. The x-axis indicates specific gene features. The top labels specify the source of the data, while the bottom labels describe the corresponding gene properties. WBCs, platelets, RBCs, and reticulocytes refer to genome-wide association studies (GWAS) of white blood cells, platelets, red blood cells, and reticulocytes, respectively. (<bold>C</bold>) Heatmap indicating the z-scaled quantitative gene features of each transgene. The x-axis indicates specific gene features. The top labels specify the source of the data, while the bottom labels describe the corresponding gene properties. Erythroblast, platelets, monocytes, and dendritic cells refer to cell types from <xref ref-type="bibr" rid="bib25">Hay et al., 2018</xref>. Gray cells indicate missing data. (<bold>D</bold>) The difference in the average value of the sigmoid parameter indicated in the right between the genes qualified into the no/yes category of the gene properties indicated in B. (<bold>E</bold>) Pearson correlation coefficient of the quantitative trans gene features (shown in C) with the sigmoid parameter value for each trans gene in the response to the modulation of dosage of the TF indicated on the left. The size of the points are inversely related to the significance of correlation, and colour indicates the direction of correlation. (<bold>F</bold>) Differences in the range of expression response for Housekeeping vs. non-Housekeeping trans genes with changes of dosage of MYB, GFI1B, and NFE2. (<bold>G</bold>) Negative correlation between haploinsufficiency score (pHaplo) and the range of the response of trans genes to the modulation of MYB.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Relationship of gene properties and transcription factor (TF)-target network properties with TF dosage responses.</title><p>(<bold>A</bold>) A regulatory network constructed based on TF-target gene data (<xref ref-type="bibr" rid="bib42">Minaeva et al., 2025</xref>) with nodes and edges coloured by betweenness. Nodes are sized by their degree. (<bold>B</bold>) Heatmap illustrating the correlation between the sigmoid parameters in response to cis-gene modulation and network centrality metrics calculated based on the regulatory networks from <xref ref-type="bibr" rid="bib42">Minaeva et al., 2025</xref>. Point size is scaled to -log10 p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Next, we collected diverse annotations for the <italic>trans</italic> genes to explore the connections between their regulatory properties, disease associations, and selective constraints concerning their response to TF dosage (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). To quantify these relationships, we assessed significant differences in belonging to these qualitative annotations using the Wilcoxon rank test (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and correlated parameters from the sigmoid model with quantitative gene metrics (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We hypothesized that genes with annotated selective constraint, numerous regulatory elements, and central positions in regulatory networks would exhibit greater robustness to TF changes. Indeed, housekeeping genes demonstrated a considerably smaller dosage response range (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Moreover, genes classified as unresponsive were enriched in the housekeeping category (odds ratio = 2.14, Fisher test <italic>p</italic>-value = 0.024). The link between selective constraint and response properties is most apparent in the <italic>MYB</italic> trans network. Specifically, the probability of haploinsufficiency (pHaplo) shows a significant negative correlation with the dynamic range of transcriptional responses (<xref ref-type="fig" rid="fig4">Figure 4G</xref>): genes under stronger constraint (higher pHaplo) display smaller dynamic ranges, indicating that dosage-sensitive genes are more tightly buffered against changes in <italic>MYB</italic> levels. This pattern was not reproduced in the other trans networks (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>The relationship between the response of <italic>trans</italic> genes and intrinsic gene properties differed between <italic>GFI1B</italic>, <italic>MYB,</italic> and <italic>NFE2 trans</italic> network responses. We also performed a similar analysis comparing the sigmoid parameters to network properties using the approach outlined by <xref ref-type="bibr" rid="bib42">Minaeva et al., 2025</xref> and obtained inconsistent results between TF regulons (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>). This suggests that the link between commonly annotated gene properties and the gene responses are complex and highly context-specific, as in our data from a single cell line, they differed between the upstream regulators that were manipulated. Thus, much more data is needed before transcriptional responses can be predicted from gene properties, and conversely, to understand the cellular mechanisms that lead to the annotated gene properties.</p></sec><sec id="s2-7"><title>Nonlinear dosage responses in complex traits and disease</title><p>Moving beyond the characterization of mechanisms of transcriptome regulation, a key question is how gradual dosage variation links to downstream cellular phenotypes, and whether these responses exhibit analogous nonlinear patterns. To address this question, we correlated our findings with the expression profiles of various cell types in order to study the myeloid differentiation process, a phenotype well-characterized for our K562 model that has been used as a reliable system for investigating erythroid differentiation within myeloid lineages (<xref ref-type="bibr" rid="bib62">Wang et al., 2013</xref>) and blood tumours (<xref ref-type="bibr" rid="bib53">Salvadores et al., 2020</xref>). Specifically, leveraging single-cell expression data for bone marrow cell types from the Human Cell Atlas and Human Biomolecular Atlas Project (<xref ref-type="bibr" rid="bib21">Granja et al., 2019</xref>), we filtered the expression data to the targeted genes in our study. After aggregating data across donors and normalising expression across cell types (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), we compared the expression patterns resulting from each unique transcription factor dosage modulation in relation to each unique cell type expression state. The ensuing correlation can then be construed as a ‘phenotype,’ signifying the similarity between the transcriptional state induced by the TF increase or decrease and the transcriptional state of a specific blood lineage cell type.</p><p>Such analyses recapitulate known biology, with <italic>GFI1B</italic> upregulation (<xref ref-type="bibr" rid="bib45">Möröy et al., 2015</xref>) and <italic>MYB</italic> downregulation (<xref ref-type="bibr" rid="bib26">Jayapal et al., 2010</xref>) being crucial factors promoting erythrocyte maturation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The downregulation of <italic>NFE2,</italic> instead, was negatively related to platelet differentiation. Analysing the correlations as inferred phenotypes suggests potential nonlinear relationships (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), but these trends should be considered hypotheses that require experimental validation. In summary, this points to cellular phenotypes resulting from gradual TF dosage modulation.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Non-linearities in transcription factor (TF) dosage responses of complex traits and disease genes.</title><p>(<bold>A</bold>) Heatmap illustrating the correlation between the mean expression of cell types and the changes in expression linked to individual TF dosage perturbations. The bar plot on the top panel represents cis gene dosage perturbation. Asterisks (*) denote correlations with 10% FDR. (<bold>B</bold>) Enrichment log(odds) ratio of non-linear TF dosage responses (ΔAIC<sub>linear-sigmoid</sub>&gt;0) in disease-related genes (OMIM genes linked to 1 or more diseases, top panel) or in GWAS blood traits-associated genes (closest expressed gene to lead GWAS variant, bottom panel). Log(odds) with Fisher’s exact test at FDR &lt;0.05 are highlighted in blue. (<bold>C</bold>) Examples of TF dosage response curves of genes both associated with disease (OMIM) and complex traits (Blood GWAS).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Transcriptional similarity among bone marrow cell types at different transcription factor (TF) dosage levels.</title><p>(<bold>A</bold>) Normalized z-score mean expression across donors for targeted genes within each bone marrow cell type (Data from the Human Cell Atlas). (<bold>B</bold>) Examples of trends of correlation of trans genes expression with the TF change in dosage. The title specifies the cis gene and the cell type for which the trans effects of TF dosage modulation have been contrasted.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100555-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Many of the analyzed <italic>trans</italic> genes are associated with physiological traits and diseases (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Understanding the nonlinear trends in the expression of these genes is of particular interest, as it helps comprehend how genes with physiological impacts may be buffered against upstream regulatory changes, and how their dosage changes as a response to upstream regulators contrasts with genetic variants that contribute to diseases and traits. Additionally, knowing the underlying dosage-to-phenotype curve of a gene can be crucial if this is considered a biomarker for identifying or treating disease. To investigate this, we analyzed whether OMIM genes for rare diseases and Mendelian traits or GWAS genes for different blood cell traits (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) that are part of the <italic>trans</italic> networks of genes affected by <italic>GFI1B</italic>, <italic>MYB,</italic> or <italic>NFE2</italic> perturbation are enriched for nonlinear dosage responses. As seen in <xref ref-type="fig" rid="fig4">Figure 4</xref>, the <italic>trans</italic> response properties of each gene are highly specific to the regulators and thus analyzed in parallel for each <italic>cis</italic> gene network. An enrichment for nonlinear responses was observed for <italic>MYB trans</italic> network genes associated with disease and for blood traits related to white blood cells and reticulocytes. These enrichments are particularly interesting given that most <italic>trans</italic> genes that were sensitive to <italic>MYB</italic> dosage modulation did not respond with a nonlinear trend (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6A</xref>).</p><p>Despite nonlinear responses not being significantly enriched among disease genes across all <italic>trans</italic> networks, the responses of the same <italic>trans</italic> gene can show very different dosage responses depending on the upstream regulator being tuned. In <xref ref-type="fig" rid="fig5">Figure 5C</xref>, we highlight several disease-associated genes (linked to one or more disease phenotypes <xref ref-type="bibr" rid="bib2">Amberger et al., 2015</xref>). <italic>FOXP1</italic>, a haploinsufficient and potentially triplosensitive transcription factor implicated in intellectual disability, exhibited a strong and dose-dependent response, particularly to varying levels of <italic>GFI1B</italic>. A similar pattern was observed for <italic>NFIA</italic>, another haploinsufficient gene involved in developmental disorders. However, it is difficult to interpret their expression response in K562 cells when their most apparent phenotypic effects likely derive from other cell types. <italic>RHB</italic> is the Rhesus blood type gene, where a common deletion of the gene causes the Rh blood type in homozygous individuals, with a strong nonlinear response to <italic>GFI1B</italic> levels. A particularly interesting gene is <italic>TUBB1</italic>, part of β-tubulin, that causes autosomal dominant macrothrombocytopenia or abnormally large platelets. Here, K562 cells are a reasonable model system, being closely related precursors to megakaryocytes that produce platelets. Interestingly, <italic>GFI1B</italic> loss also causes a macrothrombocytopenia phenotype in mice (<xref ref-type="bibr" rid="bib6">Beauchemin et al., 2017</xref>), and in our data, <italic>TUBB1</italic> expression decreases quickly as a function of decreased <italic>GFI1B</italic> expression but then plateaus at a level that corresponds to loss of one copy of <italic>TUBB1</italic>. This raises the hypothesis that low <italic>GFI1B</italic> levels may cause macrothrombocytopenia at least partially via reducing <italic>TUBB1</italic> expression.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this paper, we have investigated how gradual dosage modulation of transcription factors contributes to dosage-sensitive transcriptional regulation and investigated its potential phenotypic consequences. First, we set up an easily scalable and generalizable CRISPRi/CRISPRa approach with tiling sgRNAs for gradual titration of gene expression, with reagents that can be designed with data only of the TSS and easily ordered at scale. Alternative approaches that rely, e.g., on targeting CREs that are often unknown, dramatic overexpression, or laborious setting up of constructs for each gene are less practical for large-scale analyses. Our approach appears best suited for expression modulation in the biologically reasonable range, and other methods would be needed for dramatic overexpression or complete silencing of the target genes. Our inability to substantially increase <italic>MYB</italic> expression indicates the need for further work and larger <italic>cis</italic> gene sets to fully understand how widespread this is and to what extent this depends on <italic>cis</italic>-regulatory properties versus feedback and buffering mechanisms. Nevertheless, we believe that the approach proposed here is a useful complement to the diversifying set of tools for dosage modulation for different purposes (<xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Hawkins et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Noviello et al., 2023</xref>; <xref ref-type="bibr" rid="bib8">Chiarella et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Liu et al., 2024</xref>).</p><p>In this work, we made use of targeted transcriptome sequencing to avoid complications from the sparsity of single-cell data. While highly accurate targeted readout of the <italic>cis</italic> gene expression linked to each sgRNA is a core component of our approach, analysing <italic>trans</italic> responses could also be achieved by standard single-cell sequencing of the full transcriptome, possibly in combination with a targeted readout of transcripts of particular interest. In this study, the targeted genes were selected based on prior data of responding to <italic>GFI1B</italic>, <italic>NFE2,</italic> or <italic>MYB</italic> regulation and thus do not represent an unbiased or random sample of genes. An interesting future extension would be the addition of single-cell protein quantification to confirm that the detected mRNA levels correspond to protein levels, but this remains technically challenging.</p><p>Our results show that nonlinear responses to gradual up- and down-regulation of TF dosage are widespread and can be detected even without extreme overexpression or full knockout of the TF. The patterns of transcriptional responses are highly context-specific and vary between upstream regulators. Further work with larger sets of <italic>cis</italic> and <italic>trans</italic> genes, as well as direct quantification of cellular readouts, will be needed to fully characterise the patterns and mechanisms of downstream impacts on gene dosage. However, our findings indicate important directions for future research. First, the widespread nonlinearity suggests that inferring gene function from classical molecular biology approaches—such as drastic knockouts or knockdowns—may be limited, as these perturbations can produce effects that are both quantitatively and qualitatively different from the more modest changes that occur naturally. This may be particularly relevant for essential and highly dosage-sensitive genes, where applying our gradual dosage modulation framework can provide opportunities for functional characterization at perturbation levels that do not kill the cells. Second, we show that the effects of up- and downregulation are qualitatively and quantitatively different, which calls for increased attention to analysing both directions of effect, which also occur in natural responses to genetic variants and environmental stimuli.</p><p>Gene dosage sensitivity has typically been studied by human genetics and genomics methods (<xref ref-type="bibr" rid="bib10">Collins et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Mohammadi et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Dong et al., 2023</xref>). The experimental approach pursued in this study and the computational approaches are fundamentally different and complement each other: while human genetics is powerful for capturing the functional importance of physiological phenotypes via patterns of population variation and selective constraint, experimental approaches provide more granularity and insights into cellular mechanisms. Furthermore, while the convergence of disease effects of common and rare variants affecting the same gene is a well-known phenomenon (<xref ref-type="bibr" rid="bib3">Backman et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Freund et al., 2018</xref>), the sparsity of variants makes it difficult to properly model allelic series as a continuous dosage-to-phenotype function for individual genes. Experimental approaches can provide a powerful complement to this. Altogether, we envision that combining these perspectives into true systems genetics approaches will be a powerful way to understand how gene dosage variation contributes to human phenotypes from molecular to cellular and eventually physiological levels.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle">Reagent type (species) or resource</th><th align="left" valign="middle">Designation</th><th align="left" valign="middle">Source or reference</th><th align="left" valign="middle">Identifiers</th><th align="left" valign="middle">Additional information</th></tr></thead><tbody><tr><td>Recombinant DNA reagent</td><td>pCC_05: Lentiviral puromycin CRISPRa dCas9-VPR system</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_139090">Addgene_139090</ext-link></td><td>Used as PCR template for dCas9-VPR cassette (<xref ref-type="bibr" rid="bib31">Legut et al., 2020</xref>).</td></tr><tr><td>Recombinant DNA reagent</td><td>pGC02: Lentiviral blasticidin CRISPRi KRAB-dCas9-MeCP2 system</td><td>other</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_170068">Addgene:_170068</ext-link></td><td>Sourced from Sanjana Laboratory (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). Backbone for pJDE003 construction; digested with XbaI-FD and BamHI-FD.</td></tr><tr><td>Recombinant DNA reagent</td><td>pJDE003: Lentiviral blasticidin CRISPRa dCas9-VPR system</td><td>this study</td><td>NA</td><td>Constructed by replacing KRAB-dCas9-MeCP2 cassette in pGC02 with dCas9-VPR PCR product from pCC_05; Gibson assembled (2:1 insert:vector).</td></tr><tr><td>Recombinant DNA reagent</td><td>pGC03: Lentiviral puromycin sgRNA library cloning vector</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_170069">Addgene:_170069</ext-link></td><td>Used for cloning 96-sgRNA library (BsmBI digestion; NEBuilder HiFi assembly).</td></tr><tr><td>Recombinant DNA reagent</td><td>pMD2.G: Lentiviral envelope plasmid</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_12259">Addgene:_12259</ext-link></td><td>Envelope plasmid for lentiviral production.</td></tr><tr><td>Recombinant DNA reagent</td><td>psPAX2: Lentiviral packaging plasmid</td><td>Addgene</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_12260">Addgene:_12260</ext-link></td><td>Packaging plasmid for lentiviral production.</td></tr><tr><td>strain, strain background (<italic>Escherichia coli</italic>)</td><td>NEB 5-alpha competent cells</td><td>New England Biolabs</td><td>NEB:C2987H</td><td>Used for plasmid transformations (pJDE003 assemblies).</td></tr><tr><td>Strain, strain background (<italic>E. coli</italic>)</td><td>One Shot Stbl3 chemically competent cells</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:C737303</td><td>Used for cloning/propagating lentiviral vectors.</td></tr><tr><td>Strain, strain background (<italic>E. coli</italic>)</td><td>Endura electrocompetent cells</td><td>Lucigen</td><td>Lucigen:60242–2</td><td>Used for sgRNA library transformation by electroporation;&gt;2.5e5 transformants obtained.</td></tr><tr><td>Cell line (Human)</td><td>HEK293FT</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:R70007; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_6911">CVCL_6911</ext-link></td><td>Maintained at 37 °C, 5% CO2 in DMEM high glucose (Cytiva SH30022.01)+10% Serum Plus II (Sigma 14,009 C).</td></tr><tr><td>Cell line (Human)</td><td>K562</td><td>ATCC</td><td>ATCC:CCL-243; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0004">CVCL_0004</ext-link></td><td>Maintained at 37 °C, 5% CO2 in IMDM, GlutaMAX (ThermoFisher:31980097)+10% Serum Plus II (Sigma 14,009 C).</td></tr><tr><td>Antibody</td><td>Purified anti-CRISPR (CAS9) antibody (clone 7 A9)</td><td>BioLegend</td><td>BioLegend:844302; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2749904">AB_2749904</ext-link></td><td>Primary antibody for western blot of dCas9 (conditions not specified in excerpt).</td></tr><tr><td>Antibody</td><td>GAPDH (14 C10) Rabbit monoclonal antibody</td><td>Cell Signaling Technology</td><td>CST:2118 S; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_561053">AB_561053</ext-link></td><td>Primary antibody for loading control western blot (conditions not specified in excerpt).</td></tr><tr><td>Antibody</td><td>IRDye 800CW goat anti-mouse IgG (H+L)</td><td>LI-COR</td><td>LI-COR:925–32212</td><td>Secondary antibody for CAS9 western blot (conditions not specified in excerpt).</td></tr><tr><td>Antibody</td><td>IRDye 680RD goat anti-rabbit IgG (H+L)</td><td>LI-COR</td><td>LI-COR:925–68073</td><td>Secondary antibody for GAPDH western blot (conditions not specified in excerpt).</td></tr><tr><td>Antibody</td><td>FITC anti-human CD4 antibody (clone RPA-T4)</td><td>BioLegend</td><td>BioLegend:300505; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_314073">AB_314073</ext-link></td><td>Used for FACS validation of CRISPRa activation (day 4 and day 10/11 post-transduction).</td></tr><tr><td>antibody</td><td>APC anti-human CD19 antibody (clone HIB19)</td><td>BioLegend</td><td>BioLegend:302211; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_314241">AB_314241</ext-link></td><td>Used for FACS validation of CRISPRa activation.</td></tr><tr><td>Antibody</td><td>PE anti-human CD45 antibody (clone 2D1)</td><td>BioLegend</td><td>BioLegend:368509; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2566369">AB_2566369</ext-link></td><td>Used for FACS validation of CRISPRa activation.</td></tr><tr><td>Commercial assay or kit</td><td>Q5 High-Fidelity 2 X Master Mix</td><td>New England Biolabs</td><td>NEB:M0492L</td><td>PCR amplification of dCas9-VPR cassette.</td></tr><tr><td>Commercial assay or kit</td><td>Gibson Assembly Master Mix</td><td>New England Biolabs</td><td>NEB:E2611S</td><td>Used for Gibson assembly (2:1 insert:vector).</td></tr><tr><td>Commercial assay or kit</td><td>NEBuilder HiFi DNA Assembly kit</td><td>New England Biolabs</td><td>NEB:NEBuilder-HiFi</td><td>Used for cloning pooled sgRNA library into BsmBI-digested pGC03 (10 reactions).</td></tr><tr><td>Commercial assay or kit</td><td>Plasmid Maxiprep Kit</td><td>QIAGEN</td><td>QIAGEN:12362</td><td>Used for plasmid DNA preparation for virus production.</td></tr><tr><td>Commercial assay or kit</td><td>Maxi Fast-Ion Plasmid Kit, Endotoxin Free</td><td>IBI Scientific</td><td>IBI:IB47123</td><td>Used for sgRNA library plasmid maxiprep.</td></tr><tr><td>Commercial assay or kit</td><td>Steriflip-HV 0.45 µm filter</td><td>Millipore</td><td>Millipore:SE1M003M00</td><td>Filtration of harvested lentiviral supernatant.</td></tr><tr><td>Commercial assay or kit</td><td>Lentivirus Precipitation Solution</td><td>Alstem</td><td>Alstem:VC100</td><td>Used for lentiviral concentration (10 X or 2 X as described).</td></tr><tr><td>Commercial assay or kit</td><td>10 x Chromium Next GEM Single Cell 5’ Reagent Kit v2 (single indexing)</td><td>10 x Genomics</td><td>10 x:PN-1000265; 10 x:PN-1000190</td><td>Used for 5' single-cell library prep (two lanes; ECCITE-seq modifications).</td></tr><tr><td>Commercial assay or kit</td><td>10 x Targeted Gene Expression protocol</td><td>10 x Genomics</td><td>10 x:PN-1000248</td><td>Custom probe library used for targeted enrichment of genes of interest.</td></tr><tr><td>Commercial assay or kit</td><td>Illumina NextSeq 500/550 Mid Output v2.5 kit (150 cycles)</td><td>Illumina</td><td>Illumina:NextSeq-MidOutput-v2.5–150</td><td>Sequencing of targeted gene expression, HTO and GDO libraries.</td></tr><tr><td>Commercial assay or kit</td><td>Illumina MiSeq Reagent Kit v3 (150 cycles)</td><td>Illumina</td><td>Illumina:MiSeq-v3-150</td><td>Sequencing of dCas9 targeted enrichment and additional HTO libraries.</td></tr><tr><td>Commercial assay or kit</td><td>xGen Custom Hybridization Capture Panel (biotinylated oligos)</td><td>IDT</td><td>IDT:xGen-Custom-Panel</td><td>Custom targeted gene expression panel (final 4,405 probes;~15% discarded during design).</td></tr><tr><td>Commercial assay or kit</td><td>LookOut Mycoplasma PCR Detection Kit</td><td>Sigma-Aldrich</td><td>Sigma:MP0035</td><td>Routine mycoplasma testing (frequency not specified).</td></tr><tr><td>Peptide, recombinant protein</td><td>XbaI FastDigest (XbaI-FD)</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:FD0685</td><td>Restriction digest of pGC02.</td></tr><tr><td>Peptide, recombinant protein</td><td>BamHI FastDigest (BamHI-FD)</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:FD0054</td><td>Restriction digest of pGC02.</td></tr><tr><td>Peptide, recombinant protein</td><td>FastAP Thermosensitive Alkaline Phosphatase</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:EF0651</td><td>Vector dephosphorylation after restriction digest.</td></tr><tr><td>Peptide, recombinant protein</td><td>DpnI</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:FD1704</td><td>Digest PCR template plasmid (15 min) prior to Gibson assembly.</td></tr><tr><td>Other</td><td>DMEM high glucose with L-glutamine; without sodium pyruvate</td><td>Cytiva (HyClone)</td><td>Cytiva:SH30022.01</td><td>Used for HEK293FT culture and lentivirus resuspension media.</td></tr><tr><td>Other</td><td>IMDM, GlutaMAX</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:31980097</td><td>Used for K562 culture.</td></tr><tr><td>Other</td><td>Serum Plus II medium supplement</td><td>Sigma-Aldrich</td><td>Sigma:14,009 C</td><td>Used at 10% supplementation for HEK293FT and K562 culture.</td></tr><tr><td>Chemical compound, drug</td><td>Polyethylenimine (PEI) linear MW 25,000</td><td>Polysciences</td><td>Polysciences:23966</td><td>Used for HEK293FT transfection for lentivirus production.</td></tr><tr><td>Chemical compound, drug</td><td>Blasticidin</td><td>A.G. Scientific</td><td>A.G.Scientific:B-1247</td><td>Used at 10 µg/mL for 16 days to select dCas9-VPR K562 clones; also 5 µg/mL during sgRNA library culture as described.</td></tr><tr><td>Chemical compound, drug</td><td>Puromycin</td><td>InvivoGen</td><td>InvivoGen:ant-pr-1</td><td>Used at 2 µg/mL for sgRNA integration selection.</td></tr><tr><td>Chemical compound, drug</td><td>GlycoBlue</td><td>Thermo Fisher Scientific</td><td>ThermoFisher:AM9515</td><td>Used for DNA precipitation of pooled sgRNA library assemblies.</td></tr><tr><td>Chemical compound, drug</td><td>Isopropanol</td><td>other</td><td>NA</td><td>Used for DNA precipitation of pooled sgRNA library assemblies.</td></tr><tr><td>Chemical compound, drug</td><td>NaCl</td><td>other</td><td>NA</td><td>Used at 50 mM during DNA precipitation of pooled sgRNA library assemblies.</td></tr><tr><td>Chemical compound, drug</td><td>Ethanol 70%</td><td>other</td><td>NA</td><td>Used for washes during DNA precipitation cleanup.</td></tr><tr><td>Sequence-based reagent</td><td>PCR primers oJDE005 and oJDE006</td><td>this study</td><td>NA</td><td>Used to amplify dCas9-VPR cassette from pCC_05; primer sequences not provided in excerpt.</td></tr><tr><td>Sequence-based reagent</td><td>96-sgRNA library (ssDNA oligos, 60 bp) for gene dosage library</td><td>IDT</td><td>IDT:ssDNA-oligos-plate</td><td>96 guides pooled equimolarly to 0.2 µM; cloned into pGC03; guide sequences not provided in excerpt.</td></tr><tr><td>Software, algorithm</td><td>FastQC</td><td>Babraham Bioinformatics</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014583">SCR_014583</ext-link></td><td>Used for QC/demultiplexing of FASTQs (version not specified).</td></tr><tr><td>Software, algorithm</td><td>Cell Ranger (cellranger count)</td><td>10 x Genomics</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_017344">SCR_017344</ext-link></td><td>Used for gene expression (with targeted-panel) and guide capture analysis (Gaussian mixture model calling).</td></tr><tr><td>Software, algorithm</td><td>Seurat</td><td><xref ref-type="bibr" rid="bib22">Hao et al., 2021</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016341">SCR_016341</ext-link></td><td>Used for normalization, scaling, and UMAP; Seurat v4.3 used for NormalizeData and downstream analyses.</td></tr><tr><td>Software, algorithm</td><td>Salmon/Alevin</td><td><xref ref-type="bibr" rid="bib57">Srivastava et al., 2020</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_017036">SCR_017036</ext-link></td><td>Used for HTO quantification (version not specified).</td></tr><tr><td>Software, algorithm</td><td>Sceptre</td><td><xref ref-type="bibr" rid="bib5">Barry et al., 2021</xref></td><td>NA</td><td>Used to validate calibration of control cells (<xref ref-type="fig" rid="fig1">Figure 1e</xref>).</td></tr><tr><td>Software, algorithm</td><td>R (stats: lm, loess, AIC; drc: drm(fct =L.4()))</td><td>R Foundation; drc package</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_001905">SCR_001905</ext-link></td><td>Used for model fitting (linear, LOESS, 4-parameter sigmoid) and AIC calculation.</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>CRISPRa vector construction</title><p>To construct the vector harbouring the CRISPRa system (pJDE003), the CRISPRi (KRAB-dCas9-MeCP2) gene fusion of pGC02 was replaced with dCas9-VPR cassette, which was PCR amplified (Q5 High-Fidelity 2X Master Mix, NEB M0492L) from the plasmid pCC_05 (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>) with primers oJDE005 and oJDE006 following instructions from manufacturer. pGC02 was digested with XbaI-FD and BamHI-FD (Thermo Fisher FD0685 and FD0054) and sequentially dephosphorylated with FastAP (Thermo Fisher EF0651) following the manufacturer’s recommendations. The digested pGC02 vector and the PCR insert with the CRISPRa system (previously treated with a 15 min DpnI enzyme incubation, Thermo Fisher FD1704) were assembled by Gibson assembly using a 2:1 insert:vector ratio with Gibson Assembly Master Mix (NEB E2611S). Assemblies were transformed into NEB 5-alpha <italic>E. coli</italic> competent cells and single colonies were picked and sequence validated by Sanger sequencing. Frozen stock of the correct construct cells were regrown for plasmid Maxiprep extraction (QIAGEN 12362) for subsequent virus production.</p></sec><sec id="s4-2"><title>CRISPRa K562 cell line construction and functional validation</title><p>Lentivirus was produced by polyethylenimine linear MW 25000 (Polysciences 23966) transfection of HEK293FT cells with the transfer plasmid containing a Cas9-VPR effector, packaging plasmid psPAX2 (Addgene 12260) and envelope plasmid pMD2.G (Addgene 12259). After 72 hr post-transfection, cell media containing lentiviral particles was harvested and filtered through 0.45 μm filter Steriflip-HV (Millipore SE1M003M00). One volume of Lentivirus Precipitation Solution (Alstem VC100) was added to the collected lentivirus, mixed and stored overnight at 4°C. The mix was centrifuged for 30 min at 1,500g, and the pellet of lentiviral particles were resuspended in 1/10th of the original volume of DMEM media. Lentivirus vials were frozen at -80°C and later thawed for transduction.</p><p>To construct the monoclonal K562 cell line with the CRISPRa system, the dCas9-VPR lentivirus was transduced into one million K562 cells using 100 µl of 10X concentrated lentivirus in a total volume of 1 ml (high MOI). After 24 hr, the media was replaced with fresh IMDM, and 48 hr after transduction, blasticidin (A.G. Scientific B-1247) was added to a final concentration of 10 µg/µl for 16 days. Monoclonal cell lines were sorted by FACS (Sony Cell Sorter SH800) into a 96-well plate. The presence of dCAS9 protein in several growing clones was confirmed by western blot (Primary antibody: Purified anti-CRISPR CAS9 antibody; BioLegend 844302, Secondary antibody: LI-COR 925-32212) and protein levels were normalized to GAPDH (Primary antibody: GAPDH (14C10) Rabbit; Cell Signalling Technology 2118S. Secondary antibody: LI-COR 925-68073).</p><p>To select the final monoclonal CRISPRa cell line, the three clones with the highest protein expression in the western blot were subjected to functional validation to test for activation activity. Lentiviral guides designed from <xref ref-type="bibr" rid="bib31">Legut et al., 2020</xref> targeting CD4 (Anti-CD4 Mouse Monoclonal Antibody (FITC), BioLegend, 300505), which is lowly expressed in K562, CD19 (Anti-CD19 Mouse Monoclonal Antibody (APC), BioLegend, 302211) with null expression, and CD45 (PE anti-human CD45, BioLegend, 368509) with intermediate expression, were independently transduced into all three monoclonals, and after puromycin selection, the expression of this markers was screened by FACS at day 4 and at day 10 or 11 after transduction. The clone with the strongest and most consistent activity was selected. K562 cells were obtained as fresh stocks from ATCC for this work and not authenticated further. Cells were regularly passaged and tested for the presence of mycoplasma contamination with a Mycoplasma PCR Lookout assay.</p></sec><sec id="s4-3"><title>Gene selection for targeted sequencing and design of probe custom panel</title><p>The four selected dosage genes were GFI1B, NFE2, MYB, and TET2. GFI1B, and NFE2 were chosen due to their reported trans effects following the inhibition of their cis-CREs (<xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>). MYB was selected for being downstream of the GFI1B network, and TET2 was selected as an unrelated gene to those transcriptional networks. Both MYB and TET2 qualified as oncogene and tumour suppressor functions in K562 (<ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/">https://depmap.org/portal/</ext-link>), making them ideal choices to determine the impact of growth effects on the experiment.</p><p>The additional 88 genes captured by targeted sequencing were selected based on the significant trans effects of GFI1B and NFE2 inhibition from <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref> including two control genes, GAPDH and LHX3 genes, one highly constantly expressed ‘housekeeping gene’ and the other with no reported expression in K562 cell lines, respectively. The remaining 86 genes were selected based on Morris et al. to include (1) 29 genes that overlapped between the NFE2 and GFI1B network, (2) 47 trans genes for GFI1B, 10 trans genes for NFE2. The number of trans genes selected from each unique network was proportionally chosen, given the size of each trans network, and oversampling TFs and TF targets as defined in <xref ref-type="bibr" rid="bib20">Garcia-Alonso et al., 2019</xref>, as well as maintaining the proportional co-expression cluster structure as defined in <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>. Additional filters in the selection included a minimum expression of 0.1 mean UMI/cell and the lack of alternative 5' splice isoforms and a unique Ensembl ID.</p><p>The 10X Probe Full Custom Panel design tool was used to design the targeted gene expression probe library. A total of 687 probes (~15%) were discarded because they covered transcript regions with a median coverage per base of &lt;3 reads/bp (for medium and highly expressed genes) or &lt;1 reads/bp (for lowly expressed genes). All probes for LHX3 (0 median reads/bp) were retained. In addition, 93 probes covering the entire transcript sequence of the dCas9-VPR and KRAB-dCas9-MeCP2 transcript were included, resulting in a final total of 4405 probes. The xGen Custom Hybridization Capture Panel of biotinylated oligos was ordered and synthesized at IDT.</p></sec><sec id="s4-4"><title>Gene dosage sgRNA library design and cloning</title><p>The sgRNA library contained a total of 96 guides (51 tiling, 8 TSS, 20 attenuated, 12 enhancer, and 5 non-targeting controls). All guides were designed to not contain the U6 terminator sequence, repeats of five or more consecutive G, C, or As, as well as not falling in the genomic region where K562 cell line has alternative alleles compared to the human genome reference (Hg38). All guides were scored with FlashFry <xref ref-type="bibr" rid="bib40">McKenna and Shendure, 2018</xref> to obtain off-target and on-target activity scores that allowed the selection of the best scoring guides. Tiling guides were designed to target different regions of the promoter, TSS and beginning of the gene body of each dosage gene, spanning a total average distance of 1400 bp (TSS in the centre), each being on average distant from one another of 110 bp. The sequences of the two TSS guides were obtained from <xref ref-type="bibr" rid="bib52">Replogle et al., 2022</xref>. The sgRNAs targeting enhancers were picked from previously reported work that showed a CRISPR-based evidence of enhancer activity (GFI1B <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>), (NFE2 <xref ref-type="bibr" rid="bib64">Xie et al., 2019</xref>), (MYB <xref ref-type="bibr" rid="bib33">Li et al., 2021</xref>). The five attenuated guides for each gene were manually designed following the rules described in <xref ref-type="bibr" rid="bib27">Jost et al., 2020</xref> to span a range of activities, including a single point mutation on the best scoring guide that targeted the TSS.</p><p>Overhangs with homology regions to the pGC03 plasmid (18 bp downstream and 22 bp upstream) were added to the sgRNA sequence to be able to directly clone the ssDNA oligos into the plasmid. The 96 sgRNAs were ordered in IDT as single-stranded DNA oligos (total 60 bp) in a 96-well plate to 100 pmol scale. The oligos were pooled at equimolar concentration and diluted to a final concentration of 0.2 µM. The library was cloned into the BsmBI-digested plasmid pGC03 using 10 reactions of the NEBuilder HiFi DNA Assembly kit following the manufacturer’s instructions. All the reactions were pooled and the DNA precipitated using isopropanol, GlycoBlue (Thermo Scientific AM9515) and 50 mM NaCl for 15 min at RT. Following two washes with ethanol 70%, the assembly was resuspended with 15 µl of 0.2X TE.</p><p>To transform the library into <italic>E. coli</italic>, 1 µl of the assembly was mixed with 25 µL of Endura cells under manufacturer’s electroporation conditions, then plated onto 245 × 245 mm square LB 100 µg/ml Carbenicillin plates. The plates were grown ON, and &gt;2.5e5 transformants were obtained, ensuring the complexity of the library was maintained at &gt;1000 cells per unique sgRNA. All colonies were collected and subjected to maxiprep using the Maxi Fast-Ion Plasmid Kit, Endotoxin Free kit (IBI Scientific IB47123). The representation of the library was assessed through MiSeq shallow sequencing (Illumina).</p></sec><sec id="s4-5"><title>sgRNA lentiviral library production and cell culture assay</title><p>The lentiviral library was produced by transfecting ~80 million HEK293FT cells with a transfer plasmid containing the 96 sgRNA library, along with the packaging plasmid psPAX2 and envelope plasmid pMD2.G, using polyethylenimine linear MW 25000. The supernatant media was replaced with fresh D10 10% BSA 6 hr after transfection, and the virus was collected and filtered through 0.45 µm filters after 48 hr. The lentiviral library was then concentrated 2X using the Precipitation Lentiviral Solution, aliquoted, and stored at -80°C for subsequent transduction.</p><p>Both CRISPRi and CRISPRa K562 cell lines were independently transduced with different titers of the lentiviral sgRNA library at a low MOI (one sgRNA per cell). Twenty hours post-transduction, the cell media was replaced with fresh IMDM 10% Serum Plus II Blasticidin 5 µg/mL, and 4 hr later, Puromycin (Invivogen ant-pr-1) was added at a final concentration of 2 µg/mL to select for cells with sgRNA integration. The transduction batch with an infection rate of ~10% was selected, and cells were sorted to near purity using FACS to remove dead cells. Cells were maintained at &gt;90% survival and a maximum confluency of 700,000 cells/mL. On day 8 post-transduction, the cells were collected and prepared for cell hashing.</p></sec><sec id="s4-6"><title>Multimodal single-cell experiment and targeted sequencing</title><p>Cell hashing was performed as previously described using four hashtag-derived oligonucleotides (HTOs) in a hyperconjugation protocol (<xref ref-type="bibr" rid="bib58">Stoeckius et al., 2017</xref>). Each transduced cell line was split into four batches of 500,000 cells, resulting in a total of 8 different hashes. After incubation and washes, all 8 hashed batches were pooled together and run in two reaction lanes of the 10X Chromium Next GEM Single Cell 5’ Reagent Kit v2 (single indexing, PN-1000265, and PN-1000190). The manufacturer's protocol was followed with modifications stipulated in the ECCITE-seq protocol (<xref ref-type="bibr" rid="bib41">Mimitou et al., 2019</xref>). For each GEM reaction, 42,000 cells from the hash pool were used to obtain approximately 21,000 total cells, including ‘multiplets’ (multiple cells per droplet counts). Gene expression (cDNA), hashtags (HTOs), and guide RNA (Guide-derived oligos, GDOs) libraries were constructed following the 10x Genomics and ECCITE-seq protocols (<ext-link ext-link-type="uri" xlink:href="https://cite-seq.com/eccite-seq/">https://cite-seq.com/eccite-seq/</ext-link>) with minimal modifications. Specifically, the antibody pool protein tag library steps were ignored, and a custom-designed probe library was used to enrich the cDNA for the genes of interest in the 10X Targeted Gene Expression protocol (10X PN-1000248). The resulting libraries were sequenced using an Illumina Nextseq 500/550 Mid-Output v2.5 Kit (150 cycles). The targeted enrichment of the dCas9 transcripts was performed separately using an independent probe library and was sequenced together with additional HTO libraries using the Illumina Miseq Reagent Kit v3 (150 cycles).</p></sec><sec id="s4-7"><title>Computational and statistical analyses</title><sec id="s4-7-1"><title>From fastqs to QCed and demultiplexed UMI normalized matrices</title><p>FastQC was used to demultiplex the different samples of the three different modalities from the different 10X chip lanes, which each was processed independently. For the cDNA modality, the UMI count matrix was obtained using Cellranger <italic>count</italic>, including the <italic>targeted-panel</italic> argument to get the additional filtered matrices and summary statistics. Cells with less than 500 UMIs per cell or less than 50 genes with at least 1 UMI per cell were discarded. The top 1% of cells containing the highest UMI content were also discarded. The expression of all genes across 10X lanes were extremely reproducible (Pearson r = 0.999), showing a ~fivefold UMI count increase in contrast to the non-targeted transcriptome (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><p>For the GDO modality (sgRNAs), Cellranger count was also used using the CRISPR Guide Capture Analysis mode, which uses a Gaussian mixture model to call sgRNA per cell. The cells containing more than one sgRNA were discarded.</p><p>To classify each cell into its corresponding CRISPR system of origin (CRISPRi or CRISPRa), both the HTO modality (protein hashes) and the expression of the dCas9 targeted transcript was used. Protein hashes were called using Alevin salmon (<xref ref-type="bibr" rid="bib57">Srivastava et al., 2020</xref>), and the resulting HTO UMI matrix was mixed in with the cDNA matrix containing the expression of the CRISPRi and CRISPRa genes. This matrix was normalized and scaled using Seurat v4 (<xref ref-type="bibr" rid="bib22">Hao et al., 2021</xref>) and used to generate a UMAP based on the expression of protein hashes and the dCas9 transcripts expression. Clusters were identified and manually assigned to an HTO category given the expression pattern of each cluster. Finally, the 5% of cells classified as CRISPRi that had the lowest expression of CRISPRi transcript were discarded, as well as those 5% of CRISPRa classified cells that had the highest CRISPRi transcript expression. In total, 20,001 (10,647 CRISPRi and 9354 CRISPRa) cells passed all filters and were used for subsequent analyses.</p><p>Once each single cell was classified into a unique sgRNA perturbation and to a cell line of origin, the cDNA UMI matrices of the two 10X lanes were merged and afterwards normalized using the log1p normalization method of Seurat’s NormalizeData (Seurat version 4.3). On average, each unique sgRNA perturbation was measured in 81 and 86 cells for the CRISPRa and CRISPRi, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p></sec><sec id="s4-7-2"><title>Expression fold-change calculation and non-target sgRNA filtering</title><p>As estimates of changes in expression, we used a pseudo-bulk differential analyses approach. To get rid of the batch effects deriving from each cell line (CRISPRa vs. CRISPRa) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), for each unique perturbation, we calculated log2 fold-change of the expression of a gene against the expression of that gene in the population of cells harbouring the NTC sgRNAs of that particular cell line.</p><p>Before running the differential analyses on all targeted genes, across all unique CRISPR perturbations, we identified those NTC sgRNAs that had potential unexpected off-target activity and thus could not be used as negative controls. For all possible unique NTC sgRNA pairs, we run the above differential expression analysis on all 92 targeted genes. We discarded NTC sgRNAs that showed more than one DE gene (FDR 0.05) in more than one pairwise comparison, and the differential genes showed consistent patterns of change in expression. For this reason, cells harbouring sgRNA NTC_2 on the CRISPRa modality were discarded, as this particular perturbation showed consistent undesired activation of PPP1R14A and CTCFL genes. Additionally, we ran Sceptre (<xref ref-type="bibr" rid="bib5">Barry et al., 2021</xref>) using the resulting group of control cells to validate that our samples were calibrated correctly (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>).</p><p>Once those potential outlier NTCs were discarded, the log2FC of each targeted gene in each unique sgRNA and cell line condition was calculated. We used Seurat’s FindMarkers() function, which computes the log fold change as the difference between the average normalized gene expression in each group on the natural log scale:</p><p>Logfc = log_e(mean(expression in group 1)) - log_e(mean(expression in group 2))</p><p>This is calculated in pseudobulk where cells with the same sgRNA are grouped together and the mean expression is compared to the mean expression of cells harboring NTC guides. To calculate per-gene differential expression p-value between the two cell groups (cells with sgRNA vs cells with NTC), the Wilcoxon Rank-Sum test was used. Adjusted FDR p-values were calculated across all tests to later on call significance on DE genes. The obtained fold changes and FDRs were used for all subsequent analyses.</p></sec><sec id="s4-7-3"><title>Linear, loess, and sigmoidal model fitting</title><p>To identify the best predictive model of each cis-gene dosage to trans-gene fold change, we fitted three types of models to the data: linear (using the R <italic>lm</italic> function), a four-parameter sigmoid (using the <italic>drm(fct = L.4())</italic> function from the R dcr package) and a LOESS fit (R <italic>loess</italic> function). To evaluate and compare the goodness of fit of the linear vs. the sigmoid model taking into account overfitting, we calculated the Akaike information criterion (AIC) using the <italic>AIC</italic> function from the R stats package.</p><p>To obtain an accurate prediction of each trans gene expression given TF dosage and avoid overfitting, a 10-fold cross-validation scheme was followed by fitting the sigmoid model individually to each curve. The data was randomly split into 10 groups, where 90% of the data was used for training and the remaining 10% for testing. To obtain the values of each individual sigmoid fit for each dosage and trans gene response, the average and standard deviation of each parameter value was calculated across the 10 trained models.</p><p>Those trans genes with a slope significantly different from 0 (FDR adjusted p-value of a z-test across the 10-fold-CV parameter outputs) and with a min-to-max range significantly higher than 0.05 (FDR adjusted p-value of a z-test across the difference between the min and max asymptotes parameters in the 10-fold-CV), were classified as ‘responsive’ genes. The remaining genes were classified as ‘unresponsive.’ The top 5% trans genes of the GFI1B trans network with the largest ∆RMSE between the LOESS fit and the sigmoid fit (RMSE<sub>Sigmoid</sub> - RMSE<sub>LOESS</sub>) were classified as non-monotonic and the curve trend manually validated. For the five trans genes classified to have a non-monotonic gene expression response, their predicted expression upon TF dosage change was calculated using the LOESS model instead of the sigmoid one.</p></sec><sec id="s4-7-4"><title>Gene-specific properties</title><p>Diverse gene annotations and properties were collected to compare with the different <italic>trans</italic> genes response properties (related to <xref ref-type="fig" rid="fig4">Figure 4</xref>). Quantitative annotations included the gene biotype (Ensembl) <xref ref-type="bibr" rid="bib37">Martin et al., 2023</xref>, Housekeeping genes (<xref ref-type="bibr" rid="bib16">Eisenberg and Levanon, 2013</xref>), transcription factors (<xref ref-type="bibr" rid="bib20">Garcia-Alonso et al., 2019</xref>), genes associated with at least one disease (OMIM <xref ref-type="bibr" rid="bib2">Amberger et al., 2015</xref>), and genes associated with blood-related complex traits (obtained from <xref ref-type="bibr" rid="bib46">Morris et al., 2023</xref>).</p><p>Quantitative features included the probability of being loss-of-function intolerant scores (pLI) (<xref ref-type="bibr" rid="bib32">Lek et al., 2016</xref>) and synonymous and missense Z scores (mis z) (<xref ref-type="bibr" rid="bib32">Lek et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Samocha et al., 2014</xref>), which were obtained from the GnomAD database. Haploinsufficiency probability scores were obtained from <xref ref-type="bibr" rid="bib11">Collins et al., 2022</xref>. To obtain the number of ChIP-Seq peaks of a <italic>cis</italic> gene within the promoter region of trans-genes (n peak [cis gene]), we utilized the regulon generated by <xref ref-type="bibr" rid="bib42">Minaeva et al., 2025</xref>. This regulon was created by mapping transcription factor peaks to transcription start sites (TSS) of the 50% expressed isoforms for each gene in K562 cells, with subsequent application of a ±1 Kb proximity filter. Mean expression of genes from bone marrow cell types were obtained from <xref ref-type="bibr" rid="bib25">Hay et al., 2018</xref> and averaged across donors. The number of protein-protein interactions of each gene within the entire human proteome (Num PPIs1) was obtained from the STING database (<xref ref-type="bibr" rid="bib59">Szklarczyk et al., 2015</xref>).</p><p>To test significant differences between groups of genes (qualitative features), the Wilcoxon rank test was used. For quantitative features, Pearson correlation between parameters from the sigmoid model with quantitative gene metrics was used. Non-responsive and non-monotonic genes in each trans network were excluded.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>is CEO and co-founder with equity in Allostery Exploration Technologies, SL</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is an adviser to Qiagen and a co-founder and adviser of TruEdit Bio and OverT Bio</p></fn><fn fn-type="COI-statement" id="conf4"><p>is an advisor and has equity in Variant Bio, was a paid advisor to GSK and has received speaker honoraria from Abbvie and Merck</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100555-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All code used in this study is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/LappalainenLab/d2n_ms">GitHub</ext-link> (copy archived at <xref ref-type="bibr" rid="bib43">Minaeva and Domingo, 2026</xref>). Raw sequencing data has been submitted to GEO (accession number GSE257547).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Domingo</surname><given-names>J</given-names></name><name><surname>Minaeva</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Ziosi</surname><given-names>M</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Non-linear transcriptional responses to gradual modulation of transcription factor dosage</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE257547">GSE257547</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was funded by NIH grants R01MH106842, R01AG057422, DP2HG010099, R01HG012790, and R01GM122924; a grant from the Knut and Alice Wallenberg Foundation to SciLifeLab for research in Data-driven Life Science, DDLS (KAW 2020.0239); funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 101043238); a European Molecular Biology Organization Postdoctoral Fellowship (ALTF 345–2021) to JD; a Canadian Institutes of Health Research Banting Postdoctoral Fellowship and NIH/NHGRI (K99HG012792) to JAM.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Getz</surname><given-names>GA</given-names></name><name><surname>Graubert</surname><given-names>A</given-names></name><name><surname>Hadley</surname><given-names>K</given-names></name><name><surname>Handsaker</surname><given-names>RE</given-names></name><name><surname>Huang</surname><given-names>KH</given-names></name><name><surname>Kashin</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Meier</surname><given-names>SR</given-names></name><name><surname>Nedzel</surname><given-names>JL</given-names></name><name><surname>Nguyen</surname><given-names>DT</given-names></name><name><surname>Segrè</surname><given-names>AV</given-names></name><name><surname>Todres</surname><given-names>E</given-names></name><name><surname>Balliu</surname><given-names>B</given-names></name><name><surname>Barbeira</surname><given-names>AN</given-names></name><name><surname>Battle</surname><given-names>A</given-names></name><name><surname>Bonazzola</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>CD</given-names></name><name><surname>Castel</surname><given-names>SE</given-names></name><name><surname>Conrad</surname><given-names>DF</given-names></name><name><surname>Cotter</surname><given-names>DJ</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>de Goede</surname><given-names>OM</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name><name><surname>Einson</surname><given-names>J</given-names></name><name><surname>Engelhardt</surname><given-names>BE</given-names></name><name><surname>Eskin</surname><given-names>E</given-names></name><name><surname>Eulalio</surname><given-names>TY</given-names></name><name><surname>Ferraro</surname><given-names>NM</given-names></name><name><surname>Flynn</surname><given-names>ED</given-names></name><name><surname>Fresard</surname><given-names>L</given-names></name><name><surname>Gamazon</surname><given-names>ER</given-names></name><name><surname>Garrido-Martín</surname><given-names>D</given-names></name><name><surname>Gay</surname><given-names>NR</given-names></name><name><surname>Gloudemans</surname><given-names>MJ</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hame</surname><given-names>AR</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Hoffman</surname><given-names>PJ</given-names></name><name><surname>Hormozdiari</surname><given-names>F</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Im</surname><given-names>HK</given-names></name><name><surname>Jo</surname><given-names>B</given-names></name><name><surname>Kasela</surname><given-names>S</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name><surname>Kwong</surname><given-names>A</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Mangul</surname><given-names>S</given-names></name><name><surname>Mohammadi</surname><given-names>P</given-names></name><name><surname>Montgomery</surname><given-names>SB</given-names></name><name><surname>Muñoz-Aguirre</surname><given-names>M</given-names></name><name><surname>Nachun</surname><given-names>DC</given-names></name><name><surname>Nobel</surname><given-names>AB</given-names></name><name><surname>Oliva</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Parsana</surname><given-names>P</given-names></name><name><surname>Rao</surname><given-names>AS</given-names></name><name><surname>Reverter</surname><given-names>F</given-names></name><name><surname>Rouhana</surname><given-names>JM</given-names></name><name><surname>Sabatti</surname><given-names>C</given-names></name><name><surname>Saha</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Stranger</surname><given-names>BE</given-names></name><name><surname>Strober</surname><given-names>BJ</given-names></name><name><surname>Teran</surname><given-names>NA</given-names></name><name><surname>Viñuela</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Wright</surname><given-names>F</given-names></name><name><surname>Wucher</surname><given-names>V</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Ferreira</surname><given-names>PG</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Melé</surname><given-names>M</given-names></name><name><surname>Yeger-Lotem</surname><given-names>E</given-names></name><name><surname>Barcus</surname><given-names>ME</given-names></name><name><surname>Bradbury</surname><given-names>D</given-names></name><name><surname>Krubit</surname><given-names>T</given-names></name><name><surname>McLean</surname><given-names>JA</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Roche</surname><given-names>NV</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Sobin</surname><given-names>L</given-names></name><name><surname>Tabor</surname><given-names>DE</given-names></name><name><surname>Undale</surname><given-names>A</given-names></name><name><surname>Bridge</surname><given-names>J</given-names></name><name><surname>Brigham</surname><given-names>LE</given-names></name><name><surname>Foster</surname><given-names>BA</given-names></name><name><surname>Gillard</surname><given-names>BM</given-names></name><name><surname>Hasz</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>M</given-names></name><name><surname>Johns</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Karasik</surname><given-names>E</given-names></name><name><surname>Kopen</surname><given-names>G</given-names></name><name><surname>Leinweber</surname><given-names>WF</given-names></name><name><surname>McDonald</surname><given-names>A</given-names></name><name><surname>Moser</surname><given-names>MT</given-names></name><name><surname>Myer</surname><given-names>K</given-names></name><name><surname>Ramsey</surname><given-names>KD</given-names></name><name><surname>Roe</surname><given-names>B</given-names></name><name><surname>Shad</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>G</given-names></name><name><surname>Washington</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Jewell</surname><given-names>SD</given-names></name><name><surname>Rohrer</surname><given-names>DC</given-names></name><name><surname>Valley</surname><given-names>DR</given-names></name><name><surname>Davis</surname><given-names>DA</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Branton</surname><given-names>PA</given-names></name><name><surname>Barker</surname><given-names>LK</given-names></name><name><surname>Gardiner</surname><given-names>HM</given-names></name><name><surname>Mosavel</surname><given-names>M</given-names></name><name><surname>Siminoff</surname><given-names>LA</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name><name><surname>Juettemann</surname><given-names>T</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Powell</surname><given-names>CC</given-names></name><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Trevanion</surname><given-names>SJ</given-names></name><name><surname>Zerbino</surname><given-names>DR</given-names></name><name><surname>Abell</surname><given-names>NS</given-names></name><name><surname>Akey</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Demanelis</surname><given-names>K</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Feinberg</surname><given-names>AP</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name><name><surname>Hickey</surname><given-names>PF</given-names></name><name><surname>Jasmine</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name><name><surname>Kibriya</surname><given-names>MG</given-names></name><name><surname>Li</surname><given-names>JB</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Linder</surname><given-names>SE</given-names></name><name><surname>Pierce</surname><given-names>BL</given-names></name><name><surname>Rizzardi</surname><given-names>LF</given-names></name><name><surname>Skol</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>KS</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Carithers</surname><given-names>LJ</given-names></name><name><surname>Guan</surname><given-names>P</given-names></name><name><surname>Koester</surname><given-names>SE</given-names></name><name><surname>Little</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>HM</given-names></name><name><surname>Nierras</surname><given-names>CR</given-names></name><name><surname>Rao</surname><given-names>AK</given-names></name><name><surname>Vaught</surname><given-names>JB</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><collab>The GTEx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The GTEx Consortium atlas of genetic regulatory effects across human tissues</article-title><source>Science</source><volume>369</volume><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1126/science.aaz1776</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amberger</surname><given-names>JS</given-names></name><name><surname>Bocchini</surname><given-names>CA</given-names></name><name><surname>Schiettecatte</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>AF</given-names></name><name><surname>Hamosh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>OMIM.org: Online Mendelian Inheritance in Man (OMIM), an online catalog of human genes and genetic disorders</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D789</fpage><lpage>D798</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1205</pub-id><pub-id pub-id-type="pmid">25428349</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backman</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>AH</given-names></name><name><surname>Marcketta</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Mbatchou</surname><given-names>J</given-names></name><name><surname>Kessler</surname><given-names>MD</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Locke</surname><given-names>AE</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Yadav</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>N</given-names></name><name><surname>Gillies</surname><given-names>CE</given-names></name><name><surname>Damask</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Hawes</surname><given-names>A</given-names></name><name><surname>Maxwell</surname><given-names>E</given-names></name><name><surname>Gurski</surname><given-names>L</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Rajagopal</surname><given-names>V</given-names></name><name><surname>Mighty</surname><given-names>J</given-names></name><collab>Regeneron Genetics Center</collab><collab>DiscovEHR</collab><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Mitnaul</surname><given-names>L</given-names></name><name><surname>Stahl</surname><given-names>E</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Jorgenson</surname><given-names>E</given-names></name><name><surname>Habegger</surname><given-names>L</given-names></name><name><surname>Salerno</surname><given-names>WJ</given-names></name><name><surname>Shuldiner</surname><given-names>AR</given-names></name><name><surname>Lotta</surname><given-names>LA</given-names></name><name><surname>Overton</surname><given-names>JD</given-names></name><name><surname>Cantor</surname><given-names>MN</given-names></name><name><surname>Reid</surname><given-names>JG</given-names></name><name><surname>Yancopoulos</surname><given-names>G</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Marchini</surname><given-names>J</given-names></name><name><surname>Baras</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Ferreira</surname><given-names>MAR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Exome sequencing and analysis of 454,787 UK Biobank participants</article-title><source>Nature</source><volume>599</volume><fpage>628</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04103-z</pub-id><pub-id pub-id-type="pmid">34662886</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Lieu</surname><given-names>YK</given-names></name><name><surname>John</surname><given-names>P</given-names></name><name><surname>Reddy</surname><given-names>MVR</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Snoeck</surname><given-names>H-W</given-names></name><name><surname>Reddy</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development</article-title><source>PNAS</source><volume>111</volume><fpage>3122</fpage><lpage>3127</lpage><pub-id pub-id-type="doi">10.1073/pnas.1315464111</pub-id><pub-id pub-id-type="pmid">24516162</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Roeder</surname><given-names>K</given-names></name><name><surname>Katsevich</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SCEPTRE improves calibration and sensitivity in single-cell CRISPR screen analysis</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-021-02545-2</pub-id><pub-id pub-id-type="pmid">34930414</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beauchemin</surname><given-names>H</given-names></name><name><surname>Shooshtarizadeh</surname><given-names>P</given-names></name><name><surname>Vadnais</surname><given-names>C</given-names></name><name><surname>Vassen</surname><given-names>L</given-names></name><name><surname>Pastore</surname><given-names>YD</given-names></name><name><surname>Möröy</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Gfi1b</italic> controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes</article-title><source>Haematologica</source><volume>102</volume><fpage>484</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.3324/haematol.2016.150375</pub-id><pub-id pub-id-type="pmid">28082345</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castel</surname><given-names>SE</given-names></name><name><surname>Cervera</surname><given-names>A</given-names></name><name><surname>Mohammadi</surname><given-names>P</given-names></name><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Reverter</surname><given-names>F</given-names></name><name><surname>Wolman</surname><given-names>A</given-names></name><name><surname>Guigo</surname><given-names>R</given-names></name><name><surname>Iossifov</surname><given-names>I</given-names></name><name><surname>Vasileva</surname><given-names>A</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk</article-title><source>Nature Genetics</source><volume>50</volume><fpage>1327</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0192-y</pub-id><pub-id pub-id-type="pmid">30127527</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarella</surname><given-names>AM</given-names></name><name><surname>Butler</surname><given-names>KV</given-names></name><name><surname>Gryder</surname><given-names>BE</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>TA</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Pomella</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Hathaway</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0296-7</pub-id><pub-id pub-id-type="pmid">31712774</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claussnitzer</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Kenny</surname><given-names>EE</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>North</surname><given-names>KN</given-names></name><name><surname>Plon</surname><given-names>SE</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name><name><surname>Rotimi</surname><given-names>CN</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A brief history of human disease genetics</article-title><source>Nature</source><volume>577</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1879-7</pub-id><pub-id pub-id-type="pmid">31915397</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Khera</surname><given-names>AV</given-names></name><name><surname>Lowther</surname><given-names>C</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>A</given-names></name><name><surname>Baumann</surname><given-names>A</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Whelan</surname><given-names>CW</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Brookings</surname><given-names>T</given-names></name><name><surname>Sharpe</surname><given-names>T</given-names></name><name><surname>Stone</surname><given-names>MR</given-names></name><name><surname>Valkanas</surname><given-names>E</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Cusick</surname><given-names>C</given-names></name><name><surname>Margolin</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Post</surname><given-names>WS</given-names></name><name><surname>Chen</surname><given-names>Y-DI</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Philippakis</surname><given-names>A</given-names></name><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><collab>Genome Aggregation Database Production Team</collab><collab>Genome Aggregation Database Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>A structural variation reference for medical and population genetics</article-title><source>Nature</source><volume>581</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2287-8</pub-id><pub-id pub-id-type="pmid">32461652</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Glessner</surname><given-names>JT</given-names></name><name><surname>Porcu</surname><given-names>E</given-names></name><name><surname>Lepamets</surname><given-names>M</given-names></name><name><surname>Brandon</surname><given-names>R</given-names></name><name><surname>Lauricella</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Morley</surname><given-names>T</given-names></name><name><surname>Niestroj</surname><given-names>LM</given-names></name><name><surname>Ulirsch</surname><given-names>J</given-names></name><name><surname>Everett</surname><given-names>S</given-names></name><name><surname>Howrigan</surname><given-names>DP</given-names></name><name><surname>Boone</surname><given-names>PM</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Kellaris</surname><given-names>G</given-names></name><name><surname>Lowther</surname><given-names>C</given-names></name><name><surname>Lucente</surname><given-names>D</given-names></name><name><surname>Mohajeri</surname><given-names>K</given-names></name><name><surname>Nõukas</surname><given-names>M</given-names></name><name><surname>Nuttle</surname><given-names>X</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Trinh</surname><given-names>M</given-names></name><name><surname>Ullah</surname><given-names>F</given-names></name><name><surname>Võsa</surname><given-names>U</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Aradhya</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>EE</given-names></name><name><surname>Finucane</surname><given-names>H</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Janze</surname><given-names>A</given-names></name><name><surname>Katsanis</surname><given-names>N</given-names></name><name><surname>Matyakhina</surname><given-names>L</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Sanders</surname><given-names>D</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Hodge</surname><given-names>JC</given-names></name><name><surname>Lal</surname><given-names>D</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Meck</surname><given-names>J</given-names></name><name><surname>Mägi</surname><given-names>R</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Kutalik</surname><given-names>Z</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Sunyaev</surname><given-names>S</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><collab>Epi25 Consortium</collab><collab>Estonian Biobank Research Team</collab></person-group><year iso-8601-date="2022">2022</year><article-title>A cross-disorder dosage sensitivity map of the human genome</article-title><source>Cell</source><volume>185</volume><fpage>3041</fpage><lpage>3055</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.036</pub-id><pub-id pub-id-type="pmid">35917817</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>Rusin</surname><given-names>S</given-names></name><name><surname>East-Seletsky</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>LD</given-names></name><name><surname>Gerath</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>SE</given-names></name><name><surname>Lizotte</surname><given-names>PH</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Dwinell</surname><given-names>E</given-names></name><name><surname>Aoyama</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Harrington</surname><given-names>W</given-names></name><name><surname>Gelfand</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>TM</given-names></name><name><surname>Tomko</surname><given-names>MJ</given-names></name><name><surname>Gopal</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Bistline</surname><given-names>J</given-names></name><name><surname>Hill Meyers</surname><given-names>B</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Pellman</surname><given-names>D</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies</article-title><source>Scientific Data</source><volume>1</volume><elocation-id>140035</elocation-id><pub-id pub-id-type="doi">10.1038/sdata.2014.35</pub-id><pub-id pub-id-type="pmid">25984343</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Hartenian</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>1262</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1038/nbt.3026</pub-id><pub-id pub-id-type="pmid">25184501</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Fusi</surname><given-names>N</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Wilen</surname><given-names>C</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Listgarten</surname><given-names>J</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>An RNA-informed dosage sensitivity map reflects the intrinsic functional nature of genes</article-title><source>American Journal of Human Genetics</source><volume>110</volume><fpage>1509</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2023.08.002</pub-id><pub-id pub-id-type="pmid">37619562</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>E</given-names></name><name><surname>Levanon</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human housekeeping genes, revisited</article-title><source>Trends in Genetics</source><volume>29</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2013.05.010</pub-id><pub-id pub-id-type="pmid">23810203</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahed</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Homburger</surname><given-names>JR</given-names></name><name><surname>Patel</surname><given-names>AP</given-names></name><name><surname>Bick</surname><given-names>AG</given-names></name><name><surname>Neben</surname><given-names>CL</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Brockman</surname><given-names>D</given-names></name><name><surname>Philippakis</surname><given-names>A</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Cassa</surname><given-names>CA</given-names></name><name><surname>Lebo</surname><given-names>M</given-names></name><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Khera</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3635</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17374-3</pub-id><pub-id pub-id-type="pmid">32820175</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehrmann</surname><given-names>RSN</given-names></name><name><surname>Karjalainen</surname><given-names>JM</given-names></name><name><surname>Krajewska</surname><given-names>M</given-names></name><name><surname>Westra</surname><given-names>H-J</given-names></name><name><surname>Maloney</surname><given-names>D</given-names></name><name><surname>Simeonov</surname><given-names>A</given-names></name><name><surname>Pers</surname><given-names>TH</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Jansen</surname><given-names>RC</given-names></name><name><surname>Schultes</surname><given-names>EA</given-names></name><name><surname>van Haagen</surname><given-names>HHHBM</given-names></name><name><surname>de Vries</surname><given-names>EGE</given-names></name><name><surname>te Meerman</surname><given-names>GJ</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>van Vugt</surname><given-names>MATM</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gene expression analysis identifies global gene dosage sensitivity in cancer</article-title><source>Nature Genetics</source><volume>47</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/ng.3173</pub-id><pub-id pub-id-type="pmid">25581432</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freund</surname><given-names>MK</given-names></name><name><surname>Burch</surname><given-names>KS</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Mancuso</surname><given-names>N</given-names></name><name><surname>Kichaev</surname><given-names>G</given-names></name><name><surname>Garske</surname><given-names>KM</given-names></name><name><surname>Pan</surname><given-names>DZ</given-names></name><name><surname>Miao</surname><given-names>Z</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Pajukanta</surname><given-names>P</given-names></name><name><surname>Pasaniuc</surname><given-names>B</given-names></name><name><surname>Arboleda</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phenotype-specific enrichment of mendelian disorder genes near GWAS regions across 62 complex traits</article-title><source>American Journal of Human Genetics</source><volume>103</volume><fpage>535</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2018.08.017</pub-id><pub-id pub-id-type="pmid">30290150</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alonso</surname><given-names>L</given-names></name><name><surname>Holland</surname><given-names>CH</given-names></name><name><surname>Ibrahim</surname><given-names>MM</given-names></name><name><surname>Turei</surname><given-names>D</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Benchmark and integration of resources for the estimation of human transcription factor activities</article-title><source>Genome Research</source><volume>29</volume><fpage>1363</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1101/gr.240663.118</pub-id><pub-id pub-id-type="pmid">31340985</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granja</surname><given-names>JM</given-names></name><name><surname>Klemm</surname><given-names>S</given-names></name><name><surname>McGinnis</surname><given-names>LM</given-names></name><name><surname>Kathiria</surname><given-names>AS</given-names></name><name><surname>Mezger</surname><given-names>A</given-names></name><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Parks</surname><given-names>B</given-names></name><name><surname>Gars</surname><given-names>E</given-names></name><name><surname>Liedtke</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>GXY</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>1458</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0332-7</pub-id><pub-id pub-id-type="pmid">31792411</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name><name><surname>Zager</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Fleming</surname><given-names>LM</given-names></name><name><surname>Yeung</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>AJ</given-names></name><name><surname>McElrath</surname><given-names>JM</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><volume>184</volume><fpage>3573</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id><pub-id pub-id-type="pmid">34062119</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>T</given-names></name><name><surname>Chandrashekhar</surname><given-names>M</given-names></name><name><surname>Aregger</surname><given-names>M</given-names></name><name><surname>Steinhart</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>KR</given-names></name><name><surname>MacLeod</surname><given-names>G</given-names></name><name><surname>Mis</surname><given-names>M</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Fradet-Turcotte</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Mero</surname><given-names>P</given-names></name><name><surname>Dirks</surname><given-names>P</given-names></name><name><surname>Sidhu</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>FP</given-names></name><name><surname>Rissland</surname><given-names>OS</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Moffat</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities</article-title><source>Cell</source><volume>163</volume><fpage>1515</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.015</pub-id><pub-id pub-id-type="pmid">26627737</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>JS</given-names></name><name><surname>Silvis</surname><given-names>MR</given-names></name><name><surname>Koo</surname><given-names>B-M</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Osadnik</surname><given-names>H</given-names></name><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Hearne</surname><given-names>CC</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Todor</surname><given-names>H</given-names></name><name><surname>Gross</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mismatch-CRISPRi reveals the co-varying expression-fitness relationships of essential genes in <italic>Escherichia coli</italic> and <italic>Bacillus subtilis</italic></article-title><source>Cell Systems</source><volume>11</volume><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.09.009</pub-id><pub-id pub-id-type="pmid">33080209</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>SB</given-names></name><name><surname>Ferchen</surname><given-names>K</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Grimes</surname><given-names>HL</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Human Cell Atlas bone marrow single-cell interactive web portal</article-title><source>Experimental Hematology</source><volume>68</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2018.09.004</pub-id><pub-id pub-id-type="pmid">30243574</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayapal</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Kaldis</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Down-regulation of Myc is essential for terminal erythroid maturation</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>40252</fpage><lpage>40265</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.181073</pub-id><pub-id pub-id-type="pmid">20940306</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>DA</given-names></name><name><surname>Saunders</surname><given-names>RA</given-names></name><name><surname>Horlbeck</surname><given-names>MA</given-names></name><name><surname>Hawkins</surname><given-names>JS</given-names></name><name><surname>Scaria</surname><given-names>SM</given-names></name><name><surname>Norman</surname><given-names>TM</given-names></name><name><surname>Hussmann</surname><given-names>JA</given-names></name><name><surname>Liem</surname><given-names>CR</given-names></name><name><surname>Gross</surname><given-names>CA</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0387-5</pub-id><pub-id pub-id-type="pmid">31932729</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutzi</surname><given-names>JS</given-names></name><name><surname>Basu</surname><given-names>T</given-names></name><name><surname>Pellmann</surname><given-names>M</given-names></name><name><surname>Kaiser</surname><given-names>S</given-names></name><name><surname>Steinemann</surname><given-names>D</given-names></name><name><surname>Sanders</surname><given-names>MA</given-names></name><name><surname>Hinai</surname><given-names>ASA</given-names></name><name><surname>Zeilemaker</surname><given-names>A</given-names></name><name><surname>Bojtine Kovacs</surname><given-names>S</given-names></name><name><surname>Koellerer</surname><given-names>C</given-names></name><name><surname>Ostendorp</surname><given-names>J</given-names></name><name><surname>Aumann</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Raffoux</surname><given-names>E</given-names></name><name><surname>Cassinat</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Valk</surname><given-names>PJM</given-names></name><name><surname>Pahl</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations</article-title><source>Blood</source><volume>133</volume><fpage>1766</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-09-875047</pub-id><pub-id pub-id-type="pmid">30755419</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>L</given-names></name><name><surname>Hausser</surname><given-names>J</given-names></name><name><surname>Lotan-Pompan</surname><given-names>M</given-names></name><name><surname>Vainberg Slutskin</surname><given-names>I</given-names></name><name><surname>Alisar</surname><given-names>H</given-names></name><name><surname>Kaminski</surname><given-names>S</given-names></name><name><surname>Weinberger</surname><given-names>A</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name><name><surname>Milo</surname><given-names>R</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Massively parallel interrogation of the effects of gene expression levels on fitness</article-title><source>Cell</source><volume>166</volume><fpage>1282</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.024</pub-id><pub-id pub-id-type="pmid">27545349</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalanne</surname><given-names>JB</given-names></name><name><surname>Parker</surname><given-names>DJ</given-names></name><name><surname>Li</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spurious regulatory connections dictate the expression-fitness landscape of translation factors</article-title><source>Molecular Systems Biology</source><volume>17</volume><elocation-id>e10302</elocation-id><pub-id pub-id-type="doi">10.15252/msb.202110302</pub-id><pub-id pub-id-type="pmid">33900014</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legut</surname><given-names>M</given-names></name><name><surname>Daniloski</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>McKenzie</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wessels</surname><given-names>HH</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-throughput screens of PAM-flexible cas9 variants for gene knockout and transcriptional modulation</article-title><source>Cell Reports</source><volume>30</volume><fpage>2859</fpage><lpage>2868</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.02.010</pub-id><pub-id pub-id-type="pmid">32130891</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Tukiainen</surname><given-names>T</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>LE</given-names></name><name><surname>Estrada</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Berghout</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Deflaux</surname><given-names>N</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Howrigan</surname><given-names>D</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Kurki</surname><given-names>MI</given-names></name><name><surname>Moonshine</surname><given-names>AL</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>BP</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Tusie-Luna</surname><given-names>MT</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Won</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>DM</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Scharf</surname><given-names>JM</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tsuang</surname><given-names>MT</given-names></name><name><surname>Watkins</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Exome Aggregation Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nature19057</pub-id><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulation of MYB by distal enhancer elements in human myeloid leukemia</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>223</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03515-z</pub-id><pub-id pub-id-type="pmid">33637692</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>W</given-names></name><name><surname>Rainer</surname><given-names>P</given-names></name><name><surname>Biočanin</surname><given-names>M</given-names></name><name><surname>Gardeux</surname><given-names>V</given-names></name><name><surname>Gralak</surname><given-names>A</given-names></name><name><surname>van Mierlo</surname><given-names>G</given-names></name><name><surname>Russeil</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Deplancke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Dissecting reprogramming heterogeneity at single-cell resolution using scTF-Seq</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.01.30.577921</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Hitz</surname><given-names>BC</given-names></name><name><surname>Gabdank</surname><given-names>I</given-names></name><name><surname>Hilton</surname><given-names>JA</given-names></name><name><surname>Kagda</surname><given-names>MS</given-names></name><name><surname>Lam</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>Z</given-names></name><name><surname>Sud</surname><given-names>P</given-names></name><name><surname>Jou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Baymuradov</surname><given-names>UK</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Litton</surname><given-names>C</given-names></name><name><surname>Miyasato</surname><given-names>SR</given-names></name><name><surname>Strattan</surname><given-names>JS</given-names></name><name><surname>Jolanki</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>J-W</given-names></name><name><surname>Tanaka</surname><given-names>FY</given-names></name><name><surname>Adenekan</surname><given-names>P</given-names></name><name><surname>O’Neill</surname><given-names>E</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>New developments on the Encyclopedia of DNA elements (ENCODE) data portal</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D882</fpage><lpage>D889</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1062</pub-id><pub-id pub-id-type="pmid">31713622</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupo</surname><given-names>A</given-names></name><name><surname>Cesaro</surname><given-names>E</given-names></name><name><surname>Montano</surname><given-names>G</given-names></name><name><surname>Zurlo</surname><given-names>D</given-names></name><name><surname>Izzo</surname><given-names>P</given-names></name><name><surname>Costanzo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>KRAB-Zinc finger proteins: A repressor family displaying multiple biological functions</article-title><source>Current Genomics</source><volume>14</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.2174/13892029113149990002</pub-id><pub-id pub-id-type="pmid">24294107</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Amode</surname><given-names>MR</given-names></name><name><surname>Aneja</surname><given-names>A</given-names></name><name><surname>Austine-Orimoloye</surname><given-names>O</given-names></name><name><surname>Azov</surname><given-names>AG</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bhai</surname><given-names>J</given-names></name><name><surname>Bhurji</surname><given-names>SK</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Boddu</surname><given-names>S</given-names></name><name><surname>Branco Lins</surname><given-names>PR</given-names></name><name><surname>Brooks</surname><given-names>L</given-names></name><name><surname>Ramaraju</surname><given-names>SB</given-names></name><name><surname>Charkhchi</surname><given-names>M</given-names></name><name><surname>Cockburn</surname><given-names>A</given-names></name><name><surname>Da Rin Fiorretto</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Dodiya</surname><given-names>K</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>El Houdaigui</surname><given-names>B</given-names></name><name><surname>El Naboulsi</surname><given-names>T</given-names></name><name><surname>Fatima</surname><given-names>R</given-names></name><name><surname>Giron</surname><given-names>CG</given-names></name><name><surname>Genez</surname><given-names>T</given-names></name><name><surname>Ghattaoraya</surname><given-names>GS</given-names></name><name><surname>Martinez</surname><given-names>JG</given-names></name><name><surname>Guijarro</surname><given-names>C</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hollis</surname><given-names>Z</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Kaykala</surname><given-names>V</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Lemos</surname><given-names>D</given-names></name><name><surname>Marques-Coelho</surname><given-names>D</given-names></name><name><surname>Marugán</surname><given-names>JC</given-names></name><name><surname>Merino</surname><given-names>GA</given-names></name><name><surname>Mirabueno</surname><given-names>LP</given-names></name><name><surname>Mushtaq</surname><given-names>A</given-names></name><name><surname>Hossain</surname><given-names>SN</given-names></name><name><surname>Ogeh</surname><given-names>DN</given-names></name><name><surname>Sakthivel</surname><given-names>MP</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Piližota</surname><given-names>I</given-names></name><name><surname>Prosovetskaia</surname><given-names>I</given-names></name><name><surname>Pérez-Silva</surname><given-names>JG</given-names></name><name><surname>Salam</surname><given-names>AIA</given-names></name><name><surname>Saraiva-Agostinho</surname><given-names>N</given-names></name><name><surname>Schuilenburg</surname><given-names>H</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Sipos</surname><given-names>B</given-names></name><name><surname>Stark</surname><given-names>W</given-names></name><name><surname>Steed</surname><given-names>E</given-names></name><name><surname>Sukumaran</surname><given-names>R</given-names></name><name><surname>Sumathipala</surname><given-names>D</given-names></name><name><surname>Suner</surname><given-names>M-M</given-names></name><name><surname>Surapaneni</surname><given-names>L</given-names></name><name><surname>Sutinen</surname><given-names>K</given-names></name><name><surname>Szpak</surname><given-names>M</given-names></name><name><surname>Tricomi</surname><given-names>FF</given-names></name><name><surname>Urbina-Gómez</surname><given-names>D</given-names></name><name><surname>Veidenberg</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>TA</given-names></name><name><surname>Walts</surname><given-names>B</given-names></name><name><surname>Wass</surname><given-names>E</given-names></name><name><surname>Willhoft</surname><given-names>N</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Alvarez-Jarreta</surname><given-names>J</given-names></name><name><surname>Chakiachvili</surname><given-names>M</given-names></name><name><surname>Flint</surname><given-names>B</given-names></name><name><surname>Giorgetti</surname><given-names>S</given-names></name><name><surname>Haggerty</surname><given-names>L</given-names></name><name><surname>Ilsley</surname><given-names>GR</given-names></name><name><surname>Loveland</surname><given-names>JE</given-names></name><name><surname>Moore</surname><given-names>B</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Tate</surname><given-names>J</given-names></name><name><surname>Thybert</surname><given-names>D</given-names></name><name><surname>Trevanion</surname><given-names>SJ</given-names></name><name><surname>Winterbottom</surname><given-names>A</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Dyer</surname><given-names>S</given-names></name><name><surname>Finn</surname><given-names>RD</given-names></name><name><surname>Howe</surname><given-names>KL</given-names></name><name><surname>Harrison</surname><given-names>PW</given-names></name><name><surname>Yates</surname><given-names>AD</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ensembl 2023</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D933</fpage><lpage>D941</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac958</pub-id><pub-id pub-id-type="pmid">36318249</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurano</surname><given-names>MT</given-names></name><name><surname>Humbert</surname><given-names>R</given-names></name><name><surname>Rynes</surname><given-names>E</given-names></name><name><surname>Thurman</surname><given-names>RE</given-names></name><name><surname>Haugen</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Reynolds</surname><given-names>AP</given-names></name><name><surname>Sandstrom</surname><given-names>R</given-names></name><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Brody</surname><given-names>J</given-names></name><name><surname>Shafer</surname><given-names>A</given-names></name><name><surname>Neri</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Kutyavin</surname><given-names>T</given-names></name><name><surname>Stehling-Sun</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>AK</given-names></name><name><surname>Canfield</surname><given-names>TK</given-names></name><name><surname>Giste</surname><given-names>E</given-names></name><name><surname>Diegel</surname><given-names>M</given-names></name><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>RS</given-names></name><name><surname>Neph</surname><given-names>S</given-names></name><name><surname>Sabo</surname><given-names>PJ</given-names></name><name><surname>Heimfeld</surname><given-names>S</given-names></name><name><surname>Raubitschek</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>S</given-names></name><name><surname>Cotsapas</surname><given-names>C</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Glass</surname><given-names>I</given-names></name><name><surname>Sunyaev</surname><given-names>SR</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systematic localization of common disease-associated variation in regulatory DNA</article-title><source>Science</source><volume>337</volume><fpage>1190</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1126/science.1222794</pub-id><pub-id pub-id-type="pmid">22955828</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaw</surname><given-names>ZR</given-names></name><name><surname>O’Dushlaine</surname><given-names>C</given-names></name><name><surname>Somineni</surname><given-names>H</given-names></name><name><surname>Bereket</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Karaletsos</surname><given-names>T</given-names></name><name><surname>Casale</surname><given-names>FP</given-names></name><name><surname>Koller</surname><given-names>D</given-names></name><name><surname>Soare</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>An allelic-series rare-variant association test for candidate-gene discovery</article-title><source>American Journal of Human Genetics</source><volume>110</volume><fpage>1330</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2023.07.001</pub-id><pub-id pub-id-type="pmid">37494930</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>FlashFry: a fast and flexible tool for large-scale CRISPR target design</article-title><source>BMC Biology</source><volume>16</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-018-0545-0</pub-id><pub-id pub-id-type="pmid">29976198</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Montalbano</surname><given-names>A</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Legut</surname><given-names>M</given-names></name><name><surname>Roush</surname><given-names>T</given-names></name><name><surname>Herrera</surname><given-names>A</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Koralov</surname><given-names>SB</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells</article-title><source>Nature Methods</source><volume>16</volume><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0392-0</pub-id><pub-id pub-id-type="pmid">31011186</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minaeva</surname><given-names>M</given-names></name><name><surname>Domingo</surname><given-names>J</given-names></name><name><surname>Rentzsch</surname><given-names>P</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Specifying cellular context of transcription factor regulons for exploring context-specific gene regulation programs</article-title><source>NAR Genomics and Bioinformatics</source><volume>7</volume><elocation-id>lqae178</elocation-id><pub-id pub-id-type="doi">10.1093/nargab/lqae178</pub-id><pub-id pub-id-type="pmid">39781510</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Minaeva</surname><given-names>M</given-names></name><name><surname>Domingo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2026">2026</year><data-title>D2n_ms</data-title><version designator="swh:1:rev:e22821cbadcf11cbaad575bcc371e8427c0562f5">swh:1:rev:e22821cbadcf11cbaad575bcc371e8427c0562f5</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:c59b60f68293c9e28ea2e5d6d5d402d869e72a7c;origin=https://github.com/LappalainenLab/d2n_ms;visit=swh:1:snp:639b3ec843208190d78969ab52f50505c0ebc1a4;anchor=swh:1:rev:e22821cbadcf11cbaad575bcc371e8427c0562f5">https://archive.softwareheritage.org/swh:1:dir:c59b60f68293c9e28ea2e5d6d5d402d869e72a7c;origin=https://github.com/LappalainenLab/d2n_ms;visit=swh:1:snp:639b3ec843208190d78969ab52f50505c0ebc1a4;anchor=swh:1:rev:e22821cbadcf11cbaad575bcc371e8427c0562f5</ext-link></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>P</given-names></name><name><surname>Castel</surname><given-names>SE</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Einson</surname><given-names>J</given-names></name><name><surname>Sousa</surname><given-names>C</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Donkervoort</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Mohassel</surname><given-names>P</given-names></name><name><surname>Foley</surname><given-names>AR</given-names></name><name><surname>Wheeler</surname><given-names>HE</given-names></name><name><surname>Im</surname><given-names>HK</given-names></name><name><surname>Bonnemann</surname><given-names>CG</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic regulatory variation in populations informs transcriptome analysis in rare disease</article-title><source>Science</source><volume>366</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.aay0256</pub-id><pub-id pub-id-type="pmid">31601707</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möröy</surname><given-names>T</given-names></name><name><surname>Vassen</surname><given-names>L</given-names></name><name><surname>Wilkes</surname><given-names>B</given-names></name><name><surname>Khandanpour</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation</article-title><source>Blood</source><volume>126</volume><fpage>2561</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-06-655043</pub-id><pub-id pub-id-type="pmid">26447191</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Caragine</surname><given-names>C</given-names></name><name><surname>Daniloski</surname><given-names>Z</given-names></name><name><surname>Domingo</surname><given-names>J</given-names></name><name><surname>Barry</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><name><surname>Ziosi</surname><given-names>M</given-names></name><name><surname>Glinos</surname><given-names>DA</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Roeder</surname><given-names>K</given-names></name><name><surname>Katsevich</surname><given-names>E</given-names></name><name><surname>Lappalainen</surname><given-names>T</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Discovery of target genes and pathways at GWAS loci by pooled single-cell CRISPR screens</article-title><source>Science</source><volume>380</volume><elocation-id>eadh7699</elocation-id><pub-id pub-id-type="doi">10.1126/science.adh7699</pub-id><pub-id pub-id-type="pmid">37141313</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafavi</surname><given-names>H</given-names></name><name><surname>Spence</surname><given-names>JP</given-names></name><name><surname>Naqvi</surname><given-names>S</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Systematic differences in discovery of genetic effects on gene expression and complex traits</article-title><source>Nature Genetics</source><volume>55</volume><fpage>1866</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1038/s41588-023-01529-1</pub-id><pub-id pub-id-type="pmid">37857933</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naqvi</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Hoskens</surname><given-names>H</given-names></name><name><surname>Matthews</surname><given-names>HS</given-names></name><name><surname>Spritz</surname><given-names>RA</given-names></name><name><surname>Klein</surname><given-names>OD</given-names></name><name><surname>Hallgrímsson</surname><given-names>B</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Claes</surname><given-names>P</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Precise modulation of transcription factor levels identifies features underlying dosage sensitivity</article-title><source>Nature Genetics</source><volume>55</volume><fpage>841</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/s41588-023-01366-2</pub-id><pub-id pub-id-type="pmid">37024583</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noviello</surname><given-names>G</given-names></name><name><surname>Gjaltema</surname><given-names>RAF</given-names></name><name><surname>Schulz</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>CasTuner is a degron and CRISPR/Cas-based toolkit for analog tuning of endogenous gene expression</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>3225</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-38909-4</pub-id><pub-id pub-id-type="pmid">37270532</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polfus</surname><given-names>LM</given-names></name><name><surname>Khajuria</surname><given-names>RK</given-names></name><name><surname>Schick</surname><given-names>UM</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Pazoki</surname><given-names>R</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>M-H</given-names></name><name><surname>Auer</surname><given-names>PL</given-names></name><name><surname>Floyd</surname><given-names>JS</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>L</given-names></name><name><surname>van Rooij</surname><given-names>FJA</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Metcalf</surname><given-names>G</given-names></name><name><surname>Muzny</surname><given-names>D</given-names></name><name><surname>Veeraraghavan</surname><given-names>N</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yanek</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>LC</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Wakabayashi</surname><given-names>A</given-names></name><name><surname>Kals</surname><given-names>M</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Fox</surname><given-names>K</given-names></name><name><surname>Wallace</surname><given-names>R</given-names></name><name><surname>Franceschini</surname><given-names>N</given-names></name><name><surname>Matijevic</surname><given-names>N</given-names></name><name><surname>Rice</surname><given-names>KM</given-names></name><name><surname>Bartz</surname><given-names>TM</given-names></name><name><surname>Lyytikäinen</surname><given-names>L-P</given-names></name><name><surname>Kähönen</surname><given-names>M</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name><name><surname>Li-Gao</surname><given-names>R</given-names></name><name><surname>Mook-Kanamori</surname><given-names>DO</given-names></name><name><surname>Lettre</surname><given-names>G</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Johnson</surname><given-names>AD</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Johnsen</surname><given-names>JM</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Ganesh</surname><given-names>SK</given-names></name><name><surname>Sankaran</surname><given-names>VG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Whole-exome sequencing identifies loci associated with blood cell traits and reveals a role for alternative GFI1B splice variants in human hematopoiesis</article-title><source>American Journal of Human Genetics</source><volume>99</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.016</pub-id><pub-id pub-id-type="pmid">27486782</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Pulice</surname><given-names>JL</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Dosage amplification dictates oncogenic regulation by the <italic>NKX2-1</italic> lineage factor in lung adenocarcinoma</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.10.26.563996</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Replogle</surname><given-names>JM</given-names></name><name><surname>Saunders</surname><given-names>RA</given-names></name><name><surname>Pogson</surname><given-names>AN</given-names></name><name><surname>Hussmann</surname><given-names>JA</given-names></name><name><surname>Lenail</surname><given-names>A</given-names></name><name><surname>Guna</surname><given-names>A</given-names></name><name><surname>Mascibroda</surname><given-names>L</given-names></name><name><surname>Wagner</surname><given-names>EJ</given-names></name><name><surname>Adelman</surname><given-names>K</given-names></name><name><surname>Lithwick-Yanai</surname><given-names>G</given-names></name><name><surname>Iremadze</surname><given-names>N</given-names></name><name><surname>Oberstrass</surname><given-names>F</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Bonnar</surname><given-names>JL</given-names></name><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Norman</surname><given-names>TM</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq</article-title><source>Cell</source><volume>185</volume><fpage>2559</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.05.013</pub-id><pub-id pub-id-type="pmid">35688146</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvadores</surname><given-names>M</given-names></name><name><surname>Fuster-Tormo</surname><given-names>F</given-names></name><name><surname>Supek</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaba1862</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba1862</pub-id><pub-id pub-id-type="pmid">32937430</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Robinson</surname><given-names>EB</given-names></name><name><surname>Sanders</surname><given-names>SJ</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Sabo</surname><given-names>A</given-names></name><name><surname>McGrath</surname><given-names>LM</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Rehnström</surname><given-names>K</given-names></name><name><surname>Mallick</surname><given-names>S</given-names></name><name><surname>Kirby</surname><given-names>A</given-names></name><name><surname>Wall</surname><given-names>DP</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Roeder</surname><given-names>K</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A framework for the interpretation of de novo mutation in human disease</article-title><source>Nature Genetics</source><volume>46</volume><fpage>944</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1038/ng.3050</pub-id><pub-id pub-id-type="pmid">25086666</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-scale CRISPR pooled screens</article-title><source>Analytical Biochemistry</source><volume>532</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2016.05.014</pub-id><pub-id pub-id-type="pmid">27261176</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanson</surname><given-names>KR</given-names></name><name><surname>Hanna</surname><given-names>RE</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Strand</surname><given-names>C</given-names></name><name><surname>Sullender</surname><given-names>ME</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Goodale</surname><given-names>A</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>5416</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07901-8</pub-id><pub-id pub-id-type="pmid">30575746</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>L</given-names></name><name><surname>Sarkar</surname><given-names>H</given-names></name><name><surname>Patro</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Bayesian framework for inter-cellular information sharing improves dscRNA-seq quantification</article-title><source>Bioinformatics</source><volume>36</volume><fpage>i292</fpage><lpage>i299</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa450</pub-id><pub-id pub-id-type="pmid">32657394</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>W</given-names></name><name><surname>Houck-Loomis</surname><given-names>B</given-names></name><name><surname>Chattopadhyay</surname><given-names>PK</given-names></name><name><surname>Swerdlow</surname><given-names>H</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simultaneous epitope and transcriptome measurement in single cells</article-title><source>Nature Methods</source><volume>14</volume><fpage>865</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4380</pub-id><pub-id pub-id-type="pmid">28759029</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Forslund</surname><given-names>K</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>A</given-names></name><name><surname>Tsafou</surname><given-names>KP</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D447</fpage><lpage>D452</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id><pub-id pub-id-type="pmid">25352553</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulirsch</surname><given-names>JC</given-names></name><name><surname>Nandakumar</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Giani</surname><given-names>FC</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Rogov</surname><given-names>P</given-names></name><name><surname>Melnikov</surname><given-names>A</given-names></name><name><surname>McDonel</surname><given-names>P</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Sankaran</surname><given-names>VG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systematic functional dissection of common genetic variation affecting red blood cell traits</article-title><source>Cell</source><volume>165</volume><fpage>1530</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.04.048</pub-id><pub-id pub-id-type="pmid">27259154</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lee</surname><given-names>R</given-names></name><name><surname>Correard</surname><given-names>S</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Deregulated regulators: Disease-causing cis variants in transcription factor genes</article-title><source>Trends in Genetics</source><volume>36</volume><fpage>523</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2020.04.006</pub-id><pub-id pub-id-type="pmid">32451166</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Ruan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Wakeland</surname><given-names>EK</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic transcriptomes of human myeloid leukemia cells</article-title><source>Genomics</source><volume>102</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2013.06.004</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>NW</given-names></name><name><surname>Krupczak</surname><given-names>KM</given-names></name><name><surname>Post</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>JJ</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Armendariz</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Hon</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Global analysis of enhancer targets reveals convergent enhancer-driven regulatory modules</article-title><source>Cell Reports</source><volume>29</volume><fpage>2570</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.073</pub-id><pub-id pub-id-type="pmid">31775028</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zschocke</surname><given-names>J</given-names></name><name><surname>Byers</surname><given-names>PH</given-names></name><name><surname>Wilkie</surname><given-names>AOM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mendelian inheritance revisited: dominance and recessiveness in medical genetics</article-title><source>Nature Reviews. Genetics</source><volume>24</volume><fpage>442</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/s41576-023-00574-0</pub-id><pub-id pub-id-type="pmid">36806206</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100555.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Murim</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Seoul National University</institution><country>Republic of Korea</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> work develops a new protocol to experimentally perturb target genes across a quantitative range of expression levels in cell lines. The evidence supporting their new perturbation approach is <bold>convincing</bold>, and we propose that focusing on single modality (activation or inhibition) would be sufficient to draw their conclusions. The study will be of broad interest to scientists in the fields of functional genomics and biotechnology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100555.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this manuscript, Domingo et al. present a novel perturbation-based approach to experimentally modulate the dosage of genes in cell lines. Their approach is capable of gradually increasing and decreasing gene expression. The authors then use their approach to perturb three key transcription factors and measure the downstream effects on gene expression. Their analysis of the dosage response curve of downstream genes reveals marked non-linearity.</p><p>One of the strengths of this study is that many of the perturbations fall within the physiological range for each cis gene. This range is presumably between a single-copy state of heterozygous loss-of-function (log fold change of -1) and a three-copy state (log fold change of ~0.6). This is in contrast with CRISPRi or CRISPRa studies that attempt to maximize the effect of the perturbation, which may result in downstream effects that are not representative of physiological responses.</p><p>Another strength of the study is that various points along the dosage-response curve were assayed for each perturbed gene. This allowed the authors to effectively characterize the degree of linearity and monotonicity of each dosage-response relationship. Ultimately, the study revealed that many of these relationships are non-linear, and that the response to activation can be dramatically different than the response to inhibition.</p><p>To test their ability to gradually modulate dosage, the authors chose to measure three transcription factors and around 80 known downstream targets. As the authors themselves point out in their discussion about MYB, this biased sample of genes makes it unclear how this approach would generalize genome-wide. In addition, the data generated from this small sample of genes may not represent genome-wide patterns of dosage response. Nevertheless, this unique data set and approach represents a first step in understanding dosage-response relationships between genes.</p><p>Another point of general concern in such screens is the use of the immortalized K562 cell line. It is unclear how the biology of these cell lines translates to the in vivo biology of primary cells. However, the authors do follow up with cell-type-specific analyses (Figures 4B, 4C, and 5A) to draw correspondence between their perturbation results and the relevant biology in primary cells and complex diseases.</p><p>The conclusions of the study are generally well supported with statistical analysis throughout the manuscript. As an example, the authors utilize well-known model selection methods to identify when there was evidence for non-linear dosage response relationships.</p><p>Gradual modulation of gene dosage is a useful approach to model physiological variation in dosage. Experimental perturbation screens that use CRISPR inhibition or activation often use guide RNAs targeting the transcription start site to maximize their effect on gene expression. Generating a physiological range of variation will allow others to better model physiological conditions.</p><p>There is broad interest in the field to identify gene regulatory networks using experimental perturbation approaches. The data from this study provides a good resource for such analytical approaches, especially since both inhibition and activation were tested. In addition, these data provide a nuanced, continuous representation of the relationship between effectors and downstream targets, which may play a role in the development of more rigorous regulatory networks.</p><p>Human geneticists often focus on loss-of-function variants, which represent natural knock-down experiments, to determine the role of a gene in the biology of a trait. This study demonstrates that dosage response relationships are often non-linear, meaning that the effect of a loss-of-function variant may not necessarily carry information about increases in gene dosage. For the field, this implies that others should continue to focus on both inhibition and activation to fully characterize the relationship between gene and trait.</p><p>Comments on revisions:</p><p>Thank you for responding to our comments. We have no further comments for the authors.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100555.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This work investigates transcriptional responses to varying levels of transcription factors (TFs). The authors aim for gradual up- and down-regulation of three transcription factors GFI1B, NFE2 and MYB in K562 cells, by using a CRISPRa- and a CRISPRi line, together with sgRNAs of varying potency. Targeted single-cell RNA sequencing is then used to measure gene expression of a set of 90 genes, which were previously shown to be downstream of GFI1B and NFE2 regulation. This is followed by an extensive computational analysis of the scRNA-seq dataset. By grouping cells with the same perturbations, the authors can obtain groups of cells with varying average TF expression levels. The achieved perturbations are generally subtle, not reaching half or double doses for most samples, and up-regulation is generally weak below 1.5-fold in most cases. Even in this small range, many target genes exhibit a non-linear response. Since this is rather unexpected, it is crucial to rule out technical reasons for these observations.</p><p>Strengths:</p><p>The work showcases how a single dataset of CRISPRi/a perturbations with scRNA-seq readout and an extended computational analysis can be used to estimate transcriptome dose-responses, a general approach that likely can be built upon in the future.</p><p>Moreover, the authors highlight tiling of sgRNAs +/-1000bp around TSS as a useful approach. Compared with conventional direct TSS-targeting (+/- 200 bp), the larger sequence window allows placing more sgRNAs. Also it requires little prior knowledge of CREs, and avoids using &quot;attenuated&quot; sgRNAs which would require specialized sgRNA design.</p><p>Weaknesses:</p><p>The experiment was performed in a single replicate and it would have been reassuring to see an independent validation of the main findings, for example through measuring individual dose-response curves .</p><p>Much of the analysis depends on the estimation of log-fold changes between groups of single cells with non-targeting controls and those carrying a guide RNA driving a specific knockdown. Generally, biological replicates are recommended for differential gene expression testing (Squair et al. 2021, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-021-25960-2">https://doi.org/10.1038/s41467-021-25960-2</ext-link>). When using the FindMarkers function from the Seurat package, the authors divert from the recommendations for pseudo-bulk analysis to aggregate the raw counts (<ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/articles/de_vignette.html">https://satijalab.org/seurat/articles/de_vignette.html</ext-link>). Furthermore, differential gene expression analysis of scRNA-seq data can suffer from mis-estimations (Nguyen et al. 2023, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-023-37126-3">https://doi.org/10.1038/s41467-023-37126-3</ext-link>), and different computational tools or versions can affect these estimates strongly (Pullin et al. 2024, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13059-024-03183-0">https://doi.org/10.1186/s13059-024-03183-0</ext-link> and Rich et al. 2024, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2024.04.04.588111">https://doi.org/10.1101/2024.04.04.588111</ext-link>). Therefore it would be important to describe more precisely in the Methods how this analysis was performed, any deviations from default parameters, package versions, and at which point which values were aggregated to form &quot;pseudobulk&quot; samples.</p><p>Two different cell lines are used to construct dose-response curves, where a CRISPRi line allows gene down-regulation and the CRISPRa line allows gene upregulation. Although both lines are derived from the same parental line (K562) the expression analysis of Tet2, which is absent in the CRISPRi line, but expressed in the CRISPRa line (Fig. S1F, S3A) suggests clonal differences between the two lines. Similarly, the UMAP in S3C and the PCA in S4A suggest batch effects between the two lines. These might confound this analysis, even though all fold changes are calculated relative to the baseline expression in the respective cell line (NTC cells). Combining log2-fold changes from the two cell lines with different baseline expression into a single curve (e.g. Fig. 3) remains misleading, because different data points could be normalized to different base line expression levels.</p><p>The study estimates the relationship between TF dose and target gene expression. This requires a system that allows quantitative changes in TF expression. The data provided does not convincingly show that this condition is met, which however is an essential prerequisite for the presented conclusions. Specifically, the data shown in Fig. S3A shows that upon stronger knock-down, a subpopulation of cells appear, where the targeted TF is not detected any more (drop-outs). Also in Fig. 3B (top) suggests that the knock-down is either subtle (similar to NTCs) or strong, but intermediate knock-down (log2-FC of 0.5-1) does not occur. Although the authors argue that this is a technical effect of the scRNA-seq protocol, it is also possible that this represents a binary behavior of the CRISPRi system. Previous work has shown that CRISPRi systems with the KRAB domain largely result in binary repression and not in gradual down-regulation as suggested in this study (Bintu et al. 2016 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aab2956">https://doi.org/10.1126/science.aab2956</ext-link>), Noviello et al. 2023 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-023-38909-4">https://doi.org/10.1038/s41467-023-38909-4</ext-link>)).</p><p>One of the major conclusions of the study is that non-linear behavior is common. It would be helpful to show that this observation does not arise from the technical concerns described in the previous points. This could be done for instance with independent experimental validations.</p><p>Did the authors achieve their aims? Do the results support the conclusions?:</p><p>Some of the most important conclusions, such as the claim that non-linear responses are common, are not well supported because they rely on accurately determining the quantitative responses of trans genes, which suffers from the previously mentioned concerns.</p><p>Discussion of the likely impact of the work on the field, and the utility of the methods and data to the community:</p><p>Together with other recent publications, this work emphasizes the need to study transcription factor function with quantitative perturbations. The computational code repository contains all the valuable code with inline comments, but would have benefited from a readme file explaining the repository structure, package versions, and instructions to reproduce the analyses, including which input files or directory structure would be needed.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100555.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Domingo</surname><given-names>Júlia</given-names></name><role specific-use="author">Author</role><aff><institution>New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Minaeva</surname><given-names>Mariia</given-names></name><role specific-use="author">Author</role><aff><institution>KTH Royal Institute of Technology</institution><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>John A</given-names></name><role specific-use="author">Author</role><aff><institution>New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ghatan</surname><given-names>Samuel</given-names></name><role specific-use="author">Author</role><aff><institution>New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ziosi</surname><given-names>Marcello</given-names></name><role specific-use="author">Author</role><aff><institution>New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sanjana</surname><given-names>Neville E</given-names></name><role specific-use="author">Author</role><aff><institution>New York Genome Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lappalainen</surname><given-names>Tuuli</given-names></name><role specific-use="author">Author</role><aff><institution>KTH Royal Institute of Technology</institution><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>In this manuscript, Domingo et al. present a novel perturbation-based approach to experimentally modulate the dosage of genes in cell lines. Their approach is capable of gradually increasing and decreasing gene expression. The authors then use their approach to perturb three key transcription factors and measure the downstream effects on gene expression. Their analysis of the dosage response curve of downstream genes reveals marked non-linearity.</p><p>One of the strengths of this study is that many of the perturbations fall within the physiological range for each cis gene. This range is presumably between a single-copy state of heterozygous loss-of-function (log fold change of -1) and a three-copy state (log fold change of ~0.6). This is in contrast with CRISPRi or CRISPRa studies that attempt to maximize the effect of the perturbation, which may result in downstream effects that are not representative of physiological responses.</p><p>Another strength of the study is that various points along the dosage-response curve were assayed for each perturbed gene. This allowed the authors to effectively characterize the degree of linearity and monotonicity of each dosage-response relationship. Ultimately, the study revealed that many of these relationships are non-linear, and that the response to activation can be dramatically different than the response to inhibition.</p><p>To test their ability to gradually modulate dosage, the authors chose to measure three transcription factors and around 80 known downstream targets. As the authors themselves point out in their discussion about MYB, this biased sample of genes makes it unclear how this approach would generalize genome-wide. In addition, the data generated from this small sample of genes may not represent genome-wide patterns of dosage response. Nevertheless, this unique data set and approach represents a first step in understanding dosage-response relationships between genes.</p><p>Another point of general concern in such screens is the use of the immortalized K562 cell line. It is unclear how the biology of these cell lines translates to the in vivo biology of primary cells. However, the authors do follow up with cell-type-specific analyses (Figures 4B, 4C, and 5A) to draw a correspondence between their perturbation results and the relevant biology in primary cells and complex diseases.</p><p>The conclusions of the study are generally well supported with statistical analysis throughout the manuscript. As an example, the authors utilize well-known model selection methods to identify when there was evidence for non-linear dosage response relationships.</p><p>Gradual modulation of gene dosage is a useful approach to model physiological variation in dosage. Experimental perturbation screens that use CRISPR inhibition or activation often use guide RNAs targeting the transcription start site to maximize their effect on gene expression. Generating a physiological range of variation will allow others to better model physiological conditions.</p><p>There is broad interest in the field to identify gene regulatory networks using experimental perturbation approaches. The data from this study provides a good resource for such analytical approaches, especially since both inhibition and activation were tested. In addition, these data provide a nuanced, continuous representation of the relationship between effectors and downstream targets, which may play a role in the development of more rigorous regulatory networks.</p><p>Human geneticists often focus on loss-of-function variants, which represent natural knock-down experiments, to determine the role of a gene in the biology of a trait. This study demonstrates that dosage response relationships are often non-linear, meaning that the effect of a loss-of-function variant may not necessarily carry information about increases in gene dosage. For the field, this implies that others should continue to focus on both inhibition and activation to fully characterize the relationship between gene and trait.</p></disp-quote><p>We thank the reviewer for their thoughtful and thorough evaluation of our study. We appreciate their recognition of the strengths of our approach, particularly the ability to modulate gene dosage within a physiological range and to capture non-linear dosage-response relationships. We also agree with the reviewer’s points regarding the limitations of gene selection and the use of K562 cells, and we are encouraged that the reviewer found our follow-up analyses and statistical framework to be well-supported. We believe this work provides a valuable foundation for future genome-wide applications and more physiologically relevant perturbation studies.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>This work investigates transcriptional responses to varying levels of transcription factors (TFs). The authors aim for gradual up- and down-regulation of three transcription factors GFI1B, NFE2, and MYB in K562 cells, by using a CRISPRa- and a CRISPRi line, together with sgRNAs of varying potency. Targeted single-cell RNA sequencing is then used to measure gene expression of a set of 90 genes, which were previously shown to be downstream of GFI1B and NFE2 regulation. This is followed by an extensive computational analysis of the scRNA-seq dataset. By grouping cells with the same perturbations, the authors can obtain groups of cells with varying average TF expression levels. The achieved perturbations are generally subtle, not reaching half or double doses for most samples, and up-regulation is generally weak below 1.5-fold in most cases. Even in this small range, many target genes exhibit a non-linear response. Since this is rather unexpected, it is crucial to rule out technical reasons for these observations.</p></disp-quote><p>We thank the reviewer for their detailed and thoughtful assessment of our work. We are encouraged by their recognition of the strengths of our study, including the value of quantitative CRISPR-based perturbation coupled with single-cell transcriptomics, and its potential to inform gene regulatory network inference. Below, we address each of the concerns raised:</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The work showcases how a single dataset of CRISPRi/a perturbations with scRNA-seq readout and an extended computational analysis can be used to estimate transcriptome dose responses, a general approach that likely can be built upon in the future.</p><p>Weaknesses:</p><p>(1) The experiment was only performed in a single replicate. In the absence of an independent validation of the main findings, the robustness of the observations remains unclear.</p></disp-quote><p>We acknowledge that our study was performed in a single pooled experiment. While additional replicates would certainly strengthen the findings, in high-throughput single-cell CRISPR screens, individual cells with the same perturbation serve as effective internal replicates. This is a common practice in the field. Nevertheless, we agree that biological replicates would help control for broader technical or environmental effects.</p><disp-quote content-type="editor-comment"><p>(2) The analysis is based on the calculation of log-fold changes between groups of single cells with non-targeting controls and those carrying a guide RNA driving a specific knockdown. How the fold changes were calculated exactly remains unclear, since it is only stated that the FindMarkers function from the Seurat package was used, which is likely not optimal for quantitative estimates. Furthermore, differential gene expression analysis of scRNA-seq data can suffer from data distortion and mis-estimations (Heumos et al. 2023 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41576-023-00586-w">https://doi.org/10.1038/s41576-023-00586-w</ext-link>), Nguyen et al. 2023 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-023-37126-3">https://doi.org/10.1038/s41467-023-37126-3</ext-link>)). In general, the pseudo-bulk approach used is suitable, but the correct treatment of drop-outs in the scRNA-seq analysis is essential.</p></disp-quote><p>We thank the reviewer for highlighting recent concerns in the field. A study benchmarking association testing methods for perturb-seq data found that among existing methods, Seurat’s FindMarkers function performed the best (T. Barry et al. 2024).</p><p>In the revised Methods, we now specify the formula used to calculate fold change and clarify that the estimates are derived from the Wilcoxon test implemented in Seurat’s FindMarkers function. We also employed pseudo-bulk grouping to mitigate single-cell noise and dropout effects.</p><disp-quote content-type="editor-comment"><p>(3) Two different cell lines are used to construct dose-response curves, where a CRISPRi line allows gene down-regulation and the CRISPRa line allows gene upregulation. Although both lines are derived from the same parental line (K562) the expression analysis of Tet2, which is absent in the CRISPRi line, but expressed in the CRISPRa line (Figure S3A) suggests substantial clonal differences between the two lines. Similarly, the PCA in S4A suggests strong batch effects between the two lines. These might confound this analysis.</p></disp-quote><p>We agree that baseline differences between CRISPRi and CRISPRa lines could introduce confounding effects if not appropriately controlled for. We emphasize that all comparisons are made as fold changes relative to non-targeting control (NTC) cells within each line, thereby controlling for batch- and clone-specific baseline expression. See figures S4A and S4B.</p><disp-quote content-type="editor-comment"><p>(4) The study uses pseudo-bulk analysis to estimate the relationship between TF dose and target gene expression. This requires a system that allows quantitative changes in TF expression. The data provided does not convincingly show that this condition is met, which however is an essential prerequisite for the presented conclusions. Specifically, the data shown in Figure S3A shows that upon stronger knock-down, a subpopulation of cells appears, where the targeted TF is not detected anymore (drop-outs). Also Figure 3B (top) suggests that the knock-down is either subtle (similar to NTCs) or strong, but intermediate knock-down (log2-FC of 0.5-1) does not occur. Although the authors argue that this is a technical effect of the scRNA-seq protocol, it is also possible that this represents a binary behavior of the CRISPRi system. Previous work has shown that CRISPRi systems with the KRAB domain largely result in binary repression and not in gradual down-regulation as suggested in this study (Bintu et al. 2016 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aab2956">https://doi.org/10.1126/science.aab2956</ext-link>), Noviello et al. 2023 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-023-38909-4">https://doi.org/10.1038/s41467-023-38909-4</ext-link>)).</p></disp-quote><p>Figure S3A shows normalized expression values, not fold changes. A pseudobulk approach reduces single-cell noise and dropout effects. To test whether dropout events reflect true binary repression or technical effects, we compared trans-effects across cells with zero versus low-but-detectable target gene expression (Figure S3B). These effects were highly concordant, supporting the interpretation that dropout is largely technical in origin. We agree that KRAB-based repression can exhibit binary behavior in some contexts, but our data suggest that cells with intermediate repression exist and are biologically meaningful. In ongoing unpublished work, we pursue further analysis of these data at the single cell level, and show that for nearly all guides the dosage effects are indeed gradual rather than driven by binary effects across cells.</p><disp-quote content-type="editor-comment"><p>(5) One of the major conclusions of the study is that non-linear behavior is common. This is not surprising for gene up-regulation, since gene expression will reach a plateau at some point, but it is surprising to be observed for many genes upon TF down-regulation. Specifically, here the target gene responds to a small reduction of TF dose but shows the same response to a stronger knock-down. It would be essential to show that his observation does not arise from the technical concerns described in the previous point and it would require independent experimental validations.</p></disp-quote><p>This phenomenon—where relatively small changes in cis gene dosage can exceed the magnitude of cis gene perturbations—is not unique to our study. This also makes biological sense, since transcription factors are known to be highly dosage sensitive and generally show a smaller range of variation than many other genes (that are regulated by TFs). Empirically, these effects have been observed in previous CRISPR perturbation screens conducted in K562 cells, including those by Morris et al. (2023), Gasperini et al. (2019), and Replogle et al. (2022), to name but a few studies that our lab has personally examined the data of.</p><disp-quote content-type="editor-comment"><p>(6) One of the conclusions of the study is that guide tiling is superior to other methods such as sgRNA mismatches. However, the comparison is unfair, since different numbers of guides are used in the different approaches. Relatedly, the authors point out that tiling sometimes surpassed the effects of TSS-targeting sgRNAs, however, this was the least fair comparison (2 TSS vs 10 tiling guides) and additionally depends on the accurate annotation of TSS in the relevant cell line.</p></disp-quote><p>We do not draw this conclusion simply from observing the range achieved but from a more holistic observation. We would like to clarify that the number of sgRNAs used in each approach is proportional to the number of base pairs that can be targeted in each region: while the TSS-targeting strategy is typically constrained to a small window of a few dozen base pairs, tiling covers multiple kilobases upstream and downstream, resulting in more guides by design rather than by experimental bias. The guides with mismatches do not have a great performance for gradual upregulation.</p><p>We would also like to point out that the observation that the strongest effects can arise from regions outside the annotated TSS is not unique to our study and has been demonstrated in prior work (referenced in the text).</p><p>To address this concern, we have revised the text to clarify that we do not consider guide tiling to be inherently superior to other approaches such as sgRNA mismatches. Rather, we now describe tiling as a practical and straightforward strategy to obtain a wide range of gene dosage effects without requiring prior knowledge beyond the approximate location of the TSS. We believe this rephrasing more accurately reflects the intent and scope of our comparison.</p><disp-quote content-type="editor-comment"><p>(7) Did the authors achieve their aims? Do the results support the conclusions?: Some of the most important conclusions are not well supported because they rely on accurately determining the quantitative responses of trans genes, which suffers from the previously mentioned concerns.</p></disp-quote><p>We appreciate the reviewer’s concern, but we would have wished for a more detailed characterization of which conclusions are not supported, given that we believe our approach actually accounts for the major concerns raised above. We believe that the observation of non-linear effects is a robust conclusion that is also consistent with known biology, with this paper introducing new ways to analyze this phenomenon.</p><disp-quote content-type="editor-comment"><p>(8) Discussion of the likely impact of the work on the field, and the utility of the methods and data to the community:</p></disp-quote><p>Together with other recent publications, this work emphasizes the need to study transcription factor function with quantitative perturbations. Missing documentation of the computational code repository reduces the utility of the methods and data significantly.</p><p>Documentation is included as inline comments within the R code files to guide users through the analysis workflow.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In Figure 3C (and similar plots of dosage response curves throughout the manuscript), we initially misinterpreted the plots because we assumed that the zero log fold change on the horizontal axis was in the middle of the plot. This gives the incorrect interpretation that the trans genes are insensitive to loss of GFI1B in Figure 3C, for instance. We think it may be helpful to add a line to mark the zero log fold change point, as was done in Figure 3A.</p></disp-quote><p>We thank the reviewer for this helpful suggestion. To improve clarity, we have added a vertical line marking the zero log fold change point in Figure 3C and all similar dosage-response plots. We agree this makes the plots easier to interpret at a glance.</p><disp-quote content-type="editor-comment"><p>Similarly, for heatmaps in the style of Figure 3B, it may be nice to have a column for the non-targeting controls, which should be a white column between the perturbations that increase versus decrease GFI1B.</p></disp-quote><p>We appreciate the suggestion. However, because all perturbation effects are computed relative to the non-targeting control (NTC) cells, explicitly including a separate column for NTC in the heatmap would add limited interpretive value and could unnecessarily clutter the figure. For clarity, we have emphasized in the figure legend that the fold changes are relative to the NTC baseline.</p><disp-quote content-type="editor-comment"><p>We found it challenging to assess the degree of uncertainty in the estimation of log fold changes throughout the paper. For example, the authors state the following on line 190: &quot;We observed substantial differences in the effects of the same guide on the CRISPRi and CRISPRa backgrounds, with no significant correlation between cis gene fold-changes.&quot; This claim was challenging to assess because there are no horizontal or vertical error bars on any of the points in Figure 2A. If the log fold change estimates are very noisy, the data could be consistent with noisy observations of a correlated underlying process. Similarly, to our understanding, the dosage response curves are fit assuming that the cis log fold changes are fixed. If there is excessive noise in the estimation of these log fold changes, it may bias the estimated curves. It may be helpful to give an idea of the amount of estimation error in the cis log fold changes.</p></disp-quote><p>We agree that assessing the uncertainty in log fold change estimates is important for interpreting both the lack of correlation between CRISPRi and CRISPRa effects (Figure 2A) and the robustness of the dosage-response modeling.</p><p>In response, we have now updated Figure 2A to include both vertical and horizontal error bars, representing the standard errors of the log2 fold-change estimates for each guide in the CRISPRi and CRISPRa conditions. These error estimates were computed based on the differential expression analysis performed using the FindMarkers function in Seurat, which models gene expression differences between perturbed and control cells. We also now clarify this in the figure legend and methods.</p><disp-quote content-type="editor-comment"><p>The authors mention hierarchical clustering on line 313, which identified six clusters. Although a dendrogram is provided, these clusters are not displayed in Figure 4A. We recommend displaying these clusters alongside the dendrogram.</p></disp-quote><p>We have added colored bars indicating the clusters to improve the clarity. Thank you for the suggestion.</p><disp-quote content-type="editor-comment"><p>In Figures 4B and 4C, it was not immediately clear what some of the gene annotations meant. For example, neither the text nor the figure legend discusses what &quot;WBCs&quot;, &quot;Platelets&quot;, &quot;RBCs&quot;, or &quot;Reticulocytes&quot; mean. It would be helpful to include this somewhere other than only the methods to make the figure more clear.</p></disp-quote><p>To improve clarity, we have updated the figure legends for Figures 4B and 4C to explicitly define these abbreviations.</p><disp-quote content-type="editor-comment"><p>We struggled to interpret Figure 4E. Although the authors focus on the association of MYB with pHaplo, we would have appreciated some general discussion about the pattern of associations seen in the figure and what the authors expected to observe.</p></disp-quote><p>We have changed the paragraph to add more exposition and clarification:</p><p>“The link between selective constraint and response properties is most apparent in the MYB trans network. Specifically, the probability of haploinsufficiency (pHaplo) shows a significant negative correlation with the dynamic range of transcriptional responses (Figure 4G): genes under stronger constraint (higher pHaplo) display smaller dynamic ranges, indicating that dosage-sensitive genes are more tightly buffered against changes in MYB levels. This pattern was not reproduced in the other trans networks (Figure 4E)”.</p><disp-quote content-type="editor-comment"><p>Line 71: potentially incorrect use of &quot;rending&quot; and incorrect sentence grammar.</p></disp-quote><p>Fixed</p><disp-quote content-type="editor-comment"><p>Line 123: &quot;co-expression correlation across co-expression clusters&quot; - authors may not have intended to use &quot;co-expression&quot; twice.</p></disp-quote><p>Original sentence was correct.</p><disp-quote content-type="editor-comment"><p>Line 246: &quot;correlations&quot; is used twice in &quot;correlations gene-specific correlations.&quot;</p></disp-quote><p>Fixed.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) To show that the approach indeed allows gradual down-regulation it would be important to quantify the know-down strength with a single-cell readout for a subset of sgRNAs individually (e.g. flowfish/protein staining flow cytometry).</p></disp-quote><p>We agree that single-cell validation of knockdown strength using orthogonal approaches such as flowFISH or protein staining would provide additional support. However, such experiments fall outside the scope of the current study and are not feasible at this stage. We note that the observed transcriptomic changes and dosage responses across multiple perturbations are consistent with effective and graded modulation of gene expression.</p><disp-quote content-type="editor-comment"><p>(2) Similarly, an independent validation of the observed dose-response relationships, e.g. with individual sgRNAs, can be helpful to support the conclusions about non-linear responses.</p></disp-quote><p>Fig. S4C includes replication of trans-effects for a handful of guides used both in this study and in Morris et al. While further orthogonal validation of dose-response relationships would be valuable, such extensive additional work is not currently feasible within the scope of this study. Nonetheless, the high degree of replication in Fig. S4C as well as consistency of patterns observed across multiple sgRNAs and target genes provides strong support for the conclusions drawn from our high-throughput screen.</p><disp-quote content-type="editor-comment"><p>(3) The calculation of the log2 fold changes should be documented more precisely. To perform a pseudo-bulk analysis, the raw UMI counts should be summed up in each group (NTC, individual targeting sgRNAs), including zero counts, then the data should be normalized and the fold change should be calculated. The DESeq package for example would be useful here.</p></disp-quote><p>We have updated the methods in the manuscript to provide more exposition of how the logFC was calculated:</p><p>“In our differential expression (DE) analysis, we used Seurat’s FindMarkers() function, which computes the log fold change as the difference between the average normalized gene expression in each group on the natural log scale:</p><p>Logfc = log_e(mean(expression in group 1)) - log_e(mean(expression in group 2))</p><p>This is calculated in pseudobulk where cells with the same sgRNA are grouped together and the mean expression is compared to the mean expression of cells harbouring NTC guides. To calculate per-gene differential expression p-value between the two cell groups (cells with sgRNA vs cells with NTC), Wilcoxon Rank-Sum test was used”.</p><disp-quote content-type="editor-comment"><p>(4) A more careful characterization of the cell lines used would be helpful. First, it would be useful to include the quality controls performed when the clonal lines were selected, in the manuscript. Moreover, a transcriptome analysis in comparison to the parental cell line could be performed to show that the cell lines are comparable. In addition, it could be helpful to perform the analysis of the samples separately to see how many of the response behaviors would still be observed.</p></disp-quote><p>Details of the quality control steps used during the selection of the CRISPRa clonal line are already included in the Methods section, and Fig. S4A shows the transcriptome comparison of CRISPRi and CRISPRa lines also for non-targeting guides. Regarding the transcriptomic comparison with the parental cell line, we agree that such an analysis would be informative; however, this would require additional experiments that are not feasible within the scope of the current study. Finally, while analyzing the samples separately could provide further insight into response heterogeneity, we focused on identifying robust patterns across perturbations that are reproducible in our pooled screening framework. We believe these aggregate analyses capture the major response behaviors and support the conclusions drawn.</p><disp-quote content-type="editor-comment"><p>(5) In general we were surprised to see such strong responses in some of the trans genes, in some cases exceeding the fold changes of the cis gene perturbation more than 2x, even at the relatively modest cis gene perturbations (Figures S5-S8). How can this be explained?</p></disp-quote><p>This phenomenon—where trans gene responses can exceed the magnitude of cis gene perturbations—is not unique to our study. Similar effects have been observed in previous CRISPR perturbation screens conducted in K562 cells, including those by Morris et al. (2023), Gasperini et al. (2019), and Replogle et al. (2022).</p><p>Several factors may contribute to this pattern. One possibility is that certain trans genes are highly sensitive to transcription factor dosage, and therefore exhibit amplified expression changes in response to relatively modest upstream perturbations. Transcription factors are known to be highly dosage sensitive and generally show a smaller range of variation than many other genes (that are regulated by TFs). Mechanistically, this may involve non-linear signal propagation through regulatory networks, in which intermediate regulators or feedback loops amplify the downstream transcriptional response. While our dataset cannot fully disentangle these indirect effects, the consistency of this observation across multiple studies suggests it is a common feature of transcriptional regulation in K562 cells.</p><disp-quote content-type="editor-comment"><p>(6) In the analysis shown in Figure S3B, the correlation between cells with zero count and &gt;0 counts for the cis gene is calculated. For comparison, this analysis should also show the correlation between the cells with similar cis-gene expression and between truly different populations (e.g. NTC vs strong sgRNA).</p></disp-quote><p>The intent of Figure S3B was not to compare biologically distinct populations or perform differential expression analyses—which we have already conducted and reported elsewhere in the manuscript—but rather to assess whether fold change estimates could be biased by differences in the baseline expression of the target gene across individual cells. Specifically, we sought to determine whether cells with zero versus non-zero expression (as can result from dropouts or binary on/off repression from the KRAB-based CRISPRi system) exhibit systematic differences that could distort fold change estimation. As such, the comparisons suggested by the reviewer do not directly relate to the goal of the analysis which Figure S3B was intended to show.</p><disp-quote content-type="editor-comment"><p>(7) It is unclear why the correlation between different lanes is assessed as quality control metrics in Figure S1C. This does not substitute for replicates.</p></disp-quote><p>The intent of Figure S1C was not to serve as a general quality control metric, but rather to illustrate that the targeted transcript capture approach yielded consistent and specific signal across lanes. We acknowledge that this may have been unclear and have revised the relevant sentence in the text to avoid misinterpretation.</p><p>“We used the protein hashes and the dCas9 cDNA (indicating the presence or absence of the KRAB domain) to demultiplex and determine the cell line—CRISPRi or CRISPRa. Cells containing a single sgRNA were identified using a Gaussian mixture model (see Methods). Standard quality control procedures were applied to the scRNA-seq data (see Methods). To confirm that the targeted transcript capture approach worked as intended, we assessed concordance across capture lanes (Figure S1C)”.</p><disp-quote content-type="editor-comment"><p>(8) Figures and legends often miss important information. Figure 3B and S5-S8: what do the transparent bars represent? Figure S1A: color bar label missing. Figure S4D: what are the lines?, Figure S9A: what is the red line? In Figure S8 some of the fitted curves do not overlap with the data points, e.g. PKM. Fig. 2C: why are there more than 96 guide RNAs (see y-axis)?</p></disp-quote><p>We have addressed each point as follows:</p><p>Figure 3B: The figure legend has been updated to clarify the meaning of the transparent bars.</p><p>Figures S5–S8: There are no transparent bars in these figures; we confirmed this in the source plots.</p><p>Figure S1A: The color bar label is already described in the figure legend, but we have reformulated the caption text to make this clearer.</p><p>Figure S4D: The dashed line represents a linear regression between the x and y variables. The figure caption has been updated accordingly.</p><p>Figure S9A: We clarified that the red line shows the median ∆AIC across all genes and conditions.</p><p>Figure S8: We agree that some fitted curves (e.g., PKM) do not closely follow the data points. This reflects high noise in these specific measurements; as noted in the text, TET2 is not expected to exert strong trans effects in this context.</p><p>Figure 2C: Thank you for catching this. The y-axis numbers were incorrect because the figure displays the proportion of guides (summing to 100%), not raw counts. We have corrected the y-axis label and updated the numbers in the figure to resolve this inconsistency.</p><disp-quote content-type="editor-comment"><p>(9) The code is deposited on Github, but documentation is missing.</p></disp-quote><p>Documentation is included as inline comments within the R code files to guide users through the analysis workflow.</p><disp-quote content-type="editor-comment"><p>(10) The methods miss a list of sgRNA target sequences.</p></disp-quote><p>We thank the reviewer for this observation. A complete table containing all processed data, including the sequences of the sgRNAs used in this study, is available at the following GEO link:</p><p><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE257547&amp;format=file&amp;file=GSE257547%5Fd2n%5Fprocessed%5Fdata%2Etxt%2Egz">https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE257547&amp;format=file&amp;file=GSE257547%5Fd2n%5Fprocessed%5Fdata%2Etxt%2Egz</ext-link></p><disp-quote content-type="editor-comment"><p>(11) In some parts, the language could be more specific and/or the readability improved, for example:</p><p>Line 88: &quot;quantitative landscape&quot;.</p></disp-quote><p>Changed to “quantitative patterns”.</p><disp-quote content-type="editor-comment"><p>Lines 88-91: long sentence hard to read.</p></disp-quote><p>This complex sentence was broken up into two simpler ones:</p><p>“We uncovered quantitative patterns of how gradual changes in transcription dosage lead to linear and non-linear responses in downstream genes. Many downstream genes are associated with rare and complex diseases, with potential effects on cellular phenotypes”.</p><disp-quote content-type="editor-comment"><p>Line 110: &quot;tiling sgRNAs +/- 1000 bp from the TSS&quot;, could maybe be specified by adding that the average distance was around 100 or 110 bps?</p><p>Lines 244-246: hard to understand.</p></disp-quote><p>We struggle to see the issue here and are not sure how it can be reworded.</p><disp-quote content-type="editor-comment"><p>Lines 339-342: hard to understand.</p></disp-quote><p>These sentences have been reworded to provide more clarity.</p><disp-quote content-type="editor-comment"><p>(12) A number of typos, and errors are found in the manuscript:</p><p>Line 71: &quot;SOX2&quot; -&gt; &quot;SOX9&quot;.</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Line 73: &quot;rending&quot; -&gt; maybe &quot;raising&quot; or &quot;posing&quot;?</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Line 157: &quot;biassed&quot;.</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Line 245: &quot;exhibited correlations gene-specific correlations with&quot;.</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Multiple instances, e.g. 261: &quot;transgene&quot; -&gt; &quot;trans gene&quot;.</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Line 332: &quot;not reproduced with among the other&quot;.</p></disp-quote><p>FIXED</p><disp-quote content-type="editor-comment"><p>Figure S11: betweenness.</p></disp-quote><p>This is the correct spelling</p><disp-quote content-type="editor-comment"><p>There are more typos that we didn't list here.</p></disp-quote><p>We went through the manuscript and corrected all the spelling errors and typos.</p></body></sub-article></article>